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ABSTRACT
X-rays have been used for non-invasive high-resolution imaging of thick
biological specimens since their discovery in 1895. They are widely used for
structural imaging of bone, metal implants, and cavities in soft tissue. Recently, a
number of new contrast methodologies have emerged which are expanding Xray’s biomedical applications to functional as well as structural imaging. However,
traditional X-ray imaging provides high spatial resolution imaging through tissue
but do not measure chemical concentrations. In this dissertation, we describe an
X-ray excited optical luminescence (XEOL) technique which uses a scanning Xray beam to irradiate Gd2O2S phosphors and detect the resulting visible
luminescence through the tissue. The amount of light collected is modulated by
optical absorption in close proximity to the luminescence source. The ability to
specifically target biological processes in vivo makes nanophosphors
promising molecular imaging agents for XEOL. We also describe versatile
techniques to design and fabricate multifunctional X-ray nanophosphors. The
addition of pH-triggred drug release on our X-ray nanophosphors make it
possible to monitor pH-triggered drug release rate in real time. The iron oxide
encapsulated

X-ray

nanosctintillators

offer

MRI/fluorescence/X-ray luminescence contrast agents.

ii

promising

multimodal
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CHAPTER ONE
I. X-RAY PHOSPHORS AND THEIR APPLICATIONS
Discovery of X-ray phosphors
X-rays are electromagnetic wave with shorter wavelength (<10 nm) than the
infrared, visible, or ultraviolet light. They are widely used since they were discovered in
1895 by Wilhelm Conrad Roentgen.1-2 The research started immediately to find materials
capable of converting X-ray to visible light.

These materials were later named X-ray

phosphors (sometimes referred to as scintillators). CaWO4 powder discovered in 1896 by
Pupin was used more than 75 years. A few years later, Crookes and Regener found the
ZnS based phosphors. The excitation energy for X-ray phosphors is X-ray which is
different from the energy sources for photoluminescent and electroluminescent
phosphors. The energy sources for photo-luminescent and electroluminescent phosphors
are visible or ultraviolet light and electrons, respectively.

Principle of conversion of X-ray to visible light in X-ray phosphors
The conversion of X-ray to visible light mainly can be divided into three steps
(Figure 1.1). The first step involves multistep interaction of X-ray with the lattice of the
phosphor or absorption of X-ray by the phosphors via the Compton and photoelectric
effect. In this step, plenty of electron hole pairs are generated in the conduction bands and
thermalized in the valence bands. In the second step, electron hole pairs transport through
the crystal lattice. The last step consists in electron hole pair trapping by the luminescent
centers (doping ions) and their radioactive combination.

Figure 1.1 Schematic illustration of the three steps for the X-ray conversion to visible
light.

Characterization of X-ray phosphors
X-ray phosphors are often used in X-ray imaging screens and films for
projection imaging, fluoroscopy, and CT to convert X-ray image into light. Their most
considered characteristics are the photon-conversion efficiency, luminescence decay
time, and chemical stability. The total number of visible light photons emitted by X-ray
phosphors under 1 keV X-ray is called photon conversion efficiency or light yield. The
fundamental limit of the light yield (Y) of an activated phosphor (photons emitted/MeV)
is determined by the band gap Egap (eV) of the host material and is approximately given
by equation (1) with a maximum of close to 40% energy efficiency.3

2

(1)
The fundamental limit on light output for various phosphors. The fundamental
limit is smallest for fluorides with the largest band gap and the limit is largest for sulfides
with small band gaps. The decay rate of the luminescence center is determined by its
transition dipole moment from the excited to ground state. For most of the rare earth ions,
the decay times usually in the order of μs to ms. The chemical stability is crucial for the
phosphors especially hygroscopic materials in practical use because the hygroscopicity
limits the long term operation of these phosphors in open air.

It also limits the

applications of these particles in physiological conditions which will discuss later in the
X-ray excited optical luminescence technique.
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Table 1.1 Examples of X-ray phosphors. Reproduced from Ref. 124 with permission from
the PCCP Owner Societies.
Phosphor

Decay Maximum Emission Conversion efficiency Hygroscopicity Density g/cm3Reference
time (ns) Wavelength (nm) (visible photons/MeV)

CsI:Tl

800

550

66,000

Yes

4.51

4-6

CsI:Na

630

425

49,000

Yes

4.51

7-8

NaI:Tl

230

415

44,000

Yes

3.67

4-5, 8

LiI:Eu

1,200

475

15,000

Yes

4.08

9-10

LaBr3:Ce

35

358

61,000

Yes

5.3

11

K2LaI5: Ce

24

420

55,000

Yes

4.4

12

~1,000

435

24,000

No

3.18

4, 13

27 (25%),
450 (75%)
1,200

404

16,000

Yes

4.59

14

435

120,000

Yes

4.59

14

BaFBr:Eu

800

390

60,000

Yes

4.56

15-16

LaOBr:Tb

~1000,000

425

67,000

Yes

6.3

1, 17

LaOBr:Tm

~1000,000

374, 472

6,0000

Yes

6.1

18

ZnS:Ag

1,200

450

49,000

No

3.9

19

M’-YTaO4

3,000

337

40,000

No

7.5

16, 18

M’-YTaO4:Nb

~2,000

410

40,000

No

7.5

20-21

25

400

40,000

No

8.5

1, 22

CaF2:Eu
SrI2:Ce,Na
SrI2:Eu

BaHfO3:Ce

300

480

9,000

No

7.1

4, 23

CaWO4

8,000

425

15,800

No

6.1

24-25

CdWO4

5,000

495

20,000

No

7.9

26

24

360

20,100

No

5.35

27-28

Y3Al5O12:Ce

90~120

550

16,700

No

4.55

4-5, 29

LuAlO3:Ce

18

365

12,000

No

8.34

1, 30

Lu3Al5O12:Ce

55

530

12,500

No

6.7

31-32

Lu2SiO5:Ce

30

425

33,000

No

7.4

33

Lu2O3:Tb,Eu

~1,000

612

30,000

No

9.4

34

Gd2O3:Eu

~1,000

612

40,000

No

5.91

15, 35

Gd2O2S:Eu

~1000,000

623

60,000

No

7.3

36

Gd2O2S:Tb

Bi4Ge3O12 (BGO)

YAlO3:Ce

~1000,000

545

60,000

No

7.3

22

Gd2O2S:Pr,Ce,F

3,000

510

48,000

No

7.3

22

Gd3Ga5O12:Cr,Ce

140,000

730

40,000

No

7.1

21, 37

60

430

8,000

No

6.7

38-39

Gd2SiO5:Ce
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Discovered in 1896, CaWO4, was used for the next 80 years in X-ray phosphor
screens due to its reasonable X-ray absorption in the 20-100 keV range and blue
emission.40 However, CaWO4 suffers from low conversion efficiency (only 15,000
optical photons /Mev). Currently, alkali metal halides containing small amounts of
activator such as NaI:Tl and CsI:Tl are being widely used because of their superior
conversion efficiency (64,000 optical photons/MeV for CsI:Tl). However, most alkali
metal halides are hygroscopic requiring that the phosphors be kept moisture-free.
Recently, optical ceramic phosphors have become popular due to their light conversion
efficiency and chemical stability. Bismuth germanate oxide (BGO), a ceramic
scinitillator, is often used due to its rapid response and little or no afterglow. The speed of
response and high density make the phosphor ideal for high energy and high acquisition
rate X-ray measurements. BGO is not hygroscopic, however, its low conversion
efficiency (only 9,000 optical photons /Mev) results in poorer energy resolution than
detectors based on alkali metal halides. Rare earth oxysulfide phosphors (M2O2S:Ln, M=
Gd or Y. Ln= Ce, Pr, Eu, Tm, or Tb) are a promising class of ceramic scinitillators with
improved absorption, greater density and higher X-ray to light conversion efficiency
(60,000 optical photons/Mev).

X-ray luminescence tomography (XLT)
Though the aforementioned phosphors discussed are typically used in projection
X-ray imaging and computed tomography (CT), phosphor particles with sizes ranging
from nanometers to micrometers are used as contrast agents for X-ray luminescence
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tomography (XLT).41-42 The basic principle of XLT is based on luminescence
measurements from selectively excited nanophosphors, it’s a hybrid technique as a
complementary to CT. XLT usually collects signal in physiological or mimic
physiological environment. Although alkali metal halides containing small amounts of
activator such as NaI:Tl and CsI:Tl have great photo conversion efficiency, but they
suffer from hygroscopicity and can dissolve in physiological environment readily.
Recently, rare-earth doped oxide and oxysulfide nanoparticles have been investigated as
labels for low-background imaging using up-conversion,43 radioluminescence,18, 40 longlifetime phosphorescence,44-45 and proximity scintillation assays. These nanoparticles are
attractive imaging agents due to their chemical stability, photostability, large X-ray
absorption cross-section and scintillation efficiency, and relatively low toxicity,
especially after silica encapsulation.46 X-ray phosphors may also be coupled to
photodynamic nanoparticles to enhance reactive oxygen production,47 although their
effectiveness depends greatly upon their ability to target the reactive oxygen damage to
the nucleus or other sensitive sites.48
Through the use of a scanning luminescence X-ray microscope, Morrone
imaged the optical emission of terbium labeled actin in a single cell to obtain ~50 nm
resolution based on the selective excitation of lanthanide organo-polychelate
complexes and optical detection of their luminescence.49 The high resolution of this
technique lies in the fact that the X-ray excited luminescence is only produced in the
path of the narrow scanning X-ray beam. However, this small voxel size and weak
scintillation yield necessitated the use of a very intense X-ray dose exceeding 10 8 Gy.
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To increase the scintillation efficiency, Adam and coworkers proposed using quantum
dots for multiplexed cell labeling. 50 Alternative optical microscopy techniques have
been developed for near-field imaging in the absence of light scattering. 51-53 However,
the principle of scanning X-ray excitation can also be applied to imaging in tissues
thicker than 1 mm where optical scattering prevents high-resolution optical imaging.
In order to detect a wider variety of analytes with molecular information, Xray excited optical luminescence (XEOL) based techniques were recently developed
with lower backgrounds and lower X-ray doses. With a 1 mm X-ray beam and 1~100
cGy radiation dose, Pratx et al. developed X-ray luminescence computed tomography
(XLCT) and achieved a spatial resolution of 1 mm through tissue-mimicking
material.54 X-ray phosphors are a series of materials that convert X-ray photons to
visible photons when excited by an X-ray source. XLCT is similar to XFCT in its
sample irradiation method, however, XLCT uses photodetectors to capture the optical
photons emitted from the nanophosphors rather than an X-ray spectrometer for
secondary fluorescent X-ray detection. Because the X-ray does not scatter much in
tissue and the X-ray luminescence is only generated on the path of the narrow X-ray
beam, the optical detector need not spatially resolve the source of luminescence. As
long as the luminesence can be detected, the spatial resolution is defined by the
narrow X-ray beam. The advantages of this technique are its combination of high
sensitivity of radioluminescent nanoparticles and the high spatial localization of
collimated X-ray beams. Pratx and coworkers recently used XLCT to image the cross
sectional distribution of microsize phosphor particles in 4.5 cm of an agar tissue
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phantom.41 Carpenter recently completed a numerical phantom experiment to simulate
the X-ray dose (Gy) required to achieve a signal-to-noise ratio of 10 for varying
concentrations. They found that picomolar (ng/ml) concentrations of 10 nm X-ray
phosphor are detectable for a mammographic-like dose.55 They have also shown that
X-ray luminescence can be observed in small animal models. 54-55
Although high resolution was demonstrated using XLCT, the image is
acquired slowly by scanning the X-ray beam through the sample and rotating the
sample through 180º. In addition, there are applications such as tumor-resection
where the X-ray excitation angle is limited by geometry, and where increased rapid
acquisition is critical. Limited-angle X-ray luminescence tomography was deveoped
to address these applications based on a hybrid X-ray/optical reconstruction, which
allows XLCT spatial encoding in a limited-angle geometry, and diffuse optical spatial
discrimination for the remaining dimensions. According to the model, µg·mL -1
particle concentrations may be observed through 5 cm of tissue with ~10 mGy doses.
The limited angle technique is expected to be especially useful

in surgical

applicaions such as breast or brain excision due to rapid acquisition speed, convenient
geometric configuration, high depth resolution, and low X-ray dose.56
X-ray excited optical luminescence (XEOL) can be used not only to locate Xray phosphors in tissue, but also serve as a local light source for fluorescent and
colorimetric chemical indicators. Though optical microscopy (e.g. scanning confocal
microscopy) is an excellent technique for biomedical imaging, it has limited utility in
tissues deeper than 1 mm because almost all light is scattered, resulting in poor
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resolution.48, 57-58 The ability to specifically target biological processes in vivo makes
nanoparticles promising molecular imaging agents for X-ray excited optical
luminescence techniques. There is a urgent need of novel X-ray nanophosphors for
XEOL. However, the tranditional solid reaction methods can only provide mircosize
or even bigger size particles. 18 While the commonly used coprecipiation of host
material and doping ions by urea decomposition offers nanosized particles, most of
the work just focus on the particles synthesis and characterization. 59 Less works have
been reported on the synthesis of multifunctional X-ray nanophosphors for the
chemical imaging though tissue or in vivo study.60
This chapter has introduced the histrical discovery, mechanism of conversion
of X-rays to visible light, important characterization parameters of X-ray phosphor.
Some of the important X-ray phosphors and their characterics are also included. The
tranditional application of X-ray phosphors mainly in the X-ray detection and CT
screen. With the developmet of XLCT, the synthesis and applicaons in deep tissue
imaging or chemical detection of X-ray phosphors with nanosize attract a lot of
attention in the past decades.
Chapter II describes a novel method for high-resolution chemical imaging on
a surface embedded in tissue. The sensor surface consists of an X-ray scintillator film
coated in a thin film loaded with chemical indicator dye. A narrow scanning X-ray
beam is usedd to excite luminescence from X-ray phosphors located within the beam.
This luminescence passs through the indicator film, and the spectrum is analyzed to
measure chemical concentrations at that location. A pH sensor is demonstrated with a
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dynamic range between pH 6 to 9 and noise level of 0.05 pH units using methyl-red
dyed pH paper. The location of the interface between two types of phosphor films is
obtained with 0.30 mm spatial resolution even though the images are highly blurred
by 10 mm of chicken breast. This work has important applications for detecting pH
changes on surfaces of implanted medical devices.
Chapter III reports a high-spatial resolution imaging technique to measure
optical absorption and detect chemical and physical changes on surfaces embedded in
thick tissue. Developing sensors to measure chemical concentrations on implanted
surfaces through tissue is an important challenge for analytical chemistry and
biomedical imaging. Tissue scattering dramatically reduces the resolution of optical
imaging. In contrast, X-rays provide high spatial resolution imaging through tissue
but do not measure chemical concentrations. We describe a hybrid technique which
uses a scanning X-ray beam to irradiate Gd2O2S scintillators and detect the resulting
visible luminescence through the tissue. The amount of light collected is modulated
by optical absorption in close proximity to the luminescence source. By scanning the
X-ray beam, and measuring total amount of light collected, one can measure the local
absorption near scintillators at a resolution limited by the width of luminescence
source (i.e. the width of the X-ray excitation beam). For proof of principle, a
rectangular 1.7 mm scanning X-ray beam was used to excite a single layer of 8 μm
Gd2O2S particles, and detect the absorption of 5 nm thick silver island film through
10 mm of pork. Lifetime and spectroscopic measurements, as well changing the
refractive index of the surroundings indicate that the silver reduces the optical signal
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through attenuated total internal reflection. The technique was used to image the
dissolution of regions of the silver island film which were exposed to 1 mM of H 2O2
through 1 cm of pork tissue.
Chapter IV explores a significant and novel theranostic nanotechnology that
combines multimodal imaging with drug delivery. One of the greatest challenges in
cancer therapy is to develop methods to deliver chemotherapy agents to tumor cells while
reducing systemic toxicity to non-cancerous cells. A promising approach to localizing
drug release is to employ drug-loaded nanoparticles with coatings that release the drugs
only in the presence of specific triggers found in the target cells such as pH, enzymes, or
light. However, many parameters affect the nanoparticle distribution and drug release rate
and it is difficult to quantify drug release in situ. In this work, we show proof-ofprinciple for a “smart” radioluminescent nanocapsule with X-ray excited optical
luminescence (XEOL) spectrum that changes during release of the optically absorbing
chemotherapy drug, doxorubicin. XEOL provides an almost background-free luminescent
signal for measuring drug release from particles irradiated by a narrow X-ray beam. We
study in vitro pH triggered release rates of doxorubicin from nanocapsules coated with a
pH responsive polyelectrolyte multilayer using HPLC and XEOL spectroscopy. The
doxorubicin was loaded to over 5 % by weight, and released from the capsule with a time
constant in vitro of ~ 36 days at pH 7.4, and 21.4 hr at pH 5.0, respectively. The
Gd2O2S:Eu nanocapsules are also paramagnetic at room temperature with similar
magnetic susceptibility and similarly good MRI T2 relaxivities to Gd2O3, but the sulfur
increases the radioluminescence intensity and shifts the spectrum. Empty nanocapsules
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did not affect cell viability up to concentrations of at least 250 µg/ml. These empty
nanocapsules accumulated in a mouse liver and spleen following tail vein injection, and
could be observed in vivo using XEOL. The particles are synthesized with a versatile
template synthesis technique which allows for control of particle size and shape. The
XEOL analysis technique opens the door to non-invasive quantification of drug release as
a function of nanoparticle size, shape, surface chemistry and tissue type.
Chapter V provides a mutifunctiaonl magnetic luminescent particles by
partially etching and homogenous luminescent material coating method. When X-rays
irradiate these radioluminescence nanoparticles, they generate visible and near infrared
light that can penetrate through centimeters of tissue. X-ray luminescence tomography
(XLT) maps the location of these radioluminescent contrast agents at high resolution by
scanning a narrow X-ray beam through the tissue sample and collecting the luminescence
at every position. Adding magnetic functionality to these radioluminescent particles
would enable them to be guided, oriented, and heated using external magnetic fields,
while their location and spectrum could be imaged with XLT and complementary
magnetic resonance imaging. In this work, multifunctional monodispersed magnetic
radioluminescent nanoparticles were developed as potential drug delivery carriers and
radioluminescence imaging agents. The particles consisted of a spindle-shaped magnetic
γ-Fe2O3 core and a radioluminescent europium-doped gadolinium oxide shell. Particles
with solid iron oxide cores displayed saturation magnetizations consistent with their 13%
core volume, however, the iron oxide quenched their luminescence. In order to increase
the luminescence, we partially etched the iron oxide core in oxalic acid while preserving
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the radioluminescent shell. The core size was controlled by the etching time which in turn
affected the particles' luminescence and magnetic properties. Particles with intermediate
core sizes displayed both strong magnetophoresis and luminescence properties. They also
served as MRI contrast agents with relaxivities of up to 58 mM−1 s−1 (r2) and 120 mM−1
s−1 (r2*). These particles offer promising multimodal MRI/fluorescence/X-ray
luminescence contrast agents. Our core–shell synthesis technique offers a flexible method
to control particle size, shape, and composition for a wide range of biological
applications of magnetic/luminescent nanoparticles.
Chapter VI summarizes the work in this dissertation and also includes the
future directions.
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CHAPTTER TWO

II. HIGH-RESOLUTION CHEMICAL IMAGING THROUGH TISSUE WITH AN
X-RAY PHOSPHOR SENSOR
Introduction
Advances in medical technology over the past 50 years have resulted in an
increased number of patients who have implantable medical devices. The surface of
implanted medical devices is a region of active chemistry due to bacterial infections,
bone and tissue growth, and drug releasing stents. For example, bacteria easily colonize
implanted device surfaces and form biofilms with heterogeneous pH and oxygen
environments that are highly resistant to antibiotics.61-62 Monitoring local changes in pH
and other analytes would be valuable for detecting, studying, and monitoring in situ
biofilm growth and chemistry. However, no conventional biomedical imaging techniques
are able to perform high-resolution surface chemical imaging on surfaces. X-ray
transmission and computed tomography (CT) have limited chemical sensitivity especially
compared to optical techniques. Similarly, MRI and ultrasound provide high-resolution
tissue imaging with limited chemical sensitivity.63 Positron emission tomography (PET)
and single photon emission computed tomography (SPECT) image the location of
radiolabeled molecules and have only ~1 mm resolution due to difficulties collimating
the γ rays and due to the diffusion length of the positions. In additions, they do not have
surface specificity. Optical microscopy is a powerful technique for chemical analysis in
biological samples. A wide variety of fluorescent and absorptive dyes are available for
non-invasive, sensitive, specific, rapid, and high-resolution chemical imaging. However,
the utility of optical techniques is limited in tissues deeper than 1 mm as almost all light
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is scattered (no ballistic photons). It is difficult to reconstruct the original object from the
blurred images except at low resolution.58 Confocal microscopy improves image
resolution in thin tissues by raster scanning a focused illumination spot through the
sample and rejecting out of focus light (not originating from the focal spot) via a pinhole
aperture at the image plane. In deep tissue, however, the amount of unscattered photons
decreases exponentially with depth, and the focal spot becomes very large once it is
dominated by diffuse photons. In practice, conventional confocal microscopy works well
through tissue samples up to ~200 μm deep and under best reported conditions with twophoton NIR excitation up to about 1 mm deep.64
Moronne used a related scanning X-ray technique to image optical emission from
terbium-labeled actin in a single cell with ~50 nm resolution, far below the far-field
optical diffraction limit.49 In addition, no pH or small analyte sensitivity was shown, and
very large X-ray intensities were needed to excite light from a small number of dye
molecules/pixel rather than a much larger area and volume from many scintillating
particles in our work. Chen and co-workers demonstrated that X-ray excited phosphor
nanoparticles can transfer energy to fluorescent photodynamic dyes.47-48, 65 The suggested
that similar X-ray phosphor/fluorescent particles could serve as oxygen dosiometers.66
However, oxygen sensitivity and tissue imaging have not yet been shown. Recently,
Pratx and co-workers developed X-ray luminescence computed tomography (XLCT)
which detects the presence and location of X-ray phosphors in optically diffusive medium.
Using less than 1~100 cGy of radiation dose, they achieved a spatial resolution of 1 mm
through tissue-mimicking material based on the selective excitation of subpicomolar of

15

50 nm phosphor and optical detection of their luminescence.54 Pratx et al. also showed
that XLCT could image the cross sectional distribution of microsize phosphor particles in
1 cm of an agar tissue phantom.41 However, sensors for small chemical analyte which
can be detected using indicator dyes have not yet been explored.
Herein, we demonstrate a versatile chemical sensing technique in tissue. The
image is acquired point-by-point as the sample is scanned under the X-ray beam using a
principle analogous to other scanning probe microscopies such as nearfield scanning
optical microscopy, (NSOM). NSOM forms images by scanning a probe across a surface
and measuring the amount of light transmitted or scattered at each location.67 The
resolution of the image is largely defined by the size of the probe aperture (<50 nm for
aperture NSOM), rather than the size of the spot on the photodetector (which must be at
least as large as a diffraction limited spot). Chemical imaging NSOM is performed by
coating modulate absorbance/fluorescence.68 Our technique uses a similar scanning light
source to image local optical absorbance and chemical concentrations through tissue,
however, rather than scanning a physical probe over the surface, our light source is a
“virtual probe” formed by scanning a narrow X-ray beam across an X-ray phosphor film
on the implant surface. The narrow X-ray beam serves as a local excitation light source
for the phosphor film and the camera serves as a single pixel detector measuring total
intensity of red and green light at each sample position. The phosphors are fabricated
with a thin film containing indicator dyes to modulate the luminescence spectrum
collected through the tissue. Unlike conventional fluorescence microscopy, the X-ray
beam is far less scattered by tissue than incident visible light so the “virtual probe size”
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and image resolution is limited by the X-ray beam width. We expect that the technique
will be especially valuable for measuring concentrations of chemical analytes on the
surface of films such as detecting local changes in pH due to biofilm colonization of
implanted device surfaces.
Results and discussion
In order to demonstrate the chemical sensitivity of our novel technique as a
potential tool in diagnosis of many diseases including cancer, infection, osteolysis, and
antibiotic resistance,69-70 we developed a pH sensor by placing methyl-red dyed filter
paper over a thin layer of X-ray phosphor powder (Gd2O2S:Tb, Phosphor Technology,
Ltd. See Figure 2.1).

The phosphor and pH paper were irradiated with a narrow

rectangular X-ray beam from an X-ray diffractometer (Ultima IV, Rigaku Inc.), and the
visible luminescence was collected with an optical fiber-coupled spectrometer
(BRC741E, BWTEK, Inc. USA). (See Figure 2.2) The spectrum was collected through a
strip of pH paper at a specific pH, and then a motorized stage (MTS50 Thorlabs, Inc.)
moved the sample to another pH paper strip at a different pH. The phosphor spectrum
displayed sharp peaks which were modulated by the pH-dependent absorbance of the
filter paper.
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Figure 2.1 An X-ray excited pH sensor, formed by measuring spectra X-ray excited
luminescence through methyl red-dyed paper. (A) Schematic, (B) Spectra of Gd2O2S:Tb
through methyl red paper at different pHs, (C) Calibration curve: peak ratio as a function
of pH. Error bars represent the standard deviation of 5 replicable trials. Reprinted with
permission from ref. 112. Copyright 2011 American Chemical Society.
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Figure 2.2 Photograph of experimental setup for measuring pH by detecting
luminescence spectrum through methyl red dyed filter paper. Reprinted with permission
from ref. 112. Copyright 2011 American Chemical Society.
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Figure 2.3 XRD patterns of the phosphor powders. (a) Gd2O2S:Tb (green) phosphor, (b)
Gd2O2S:Eu (red) phosphor. Reprinted with permission from ref. 112. Copyright 2011
American Chemical Society.
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Rare earth oxysulfide phosphors have been widely used for X-ray detectors due to
their robustness and large quantum efficiency for X-ray to visible light conversion
(~60,000 visible photons/MeV).16, 71 Previous studies also showed rare earth ions such as
Gd and Eu are not highly toxic: LD50 for intravenous injection is 10-100mg/kg.72 For
example, gadolinium MRI contrast agents are used in 20 million scans per year with an
average dose of 1.2 g/patient.73 The relatively low toxicity, chemical stability, and
resistance to photobeaching of rare earth oxysulfide phosphors make them ideal labels in
physiology conditions.74-75 For our application, the multiple narrow and intense spectral
luminescence peaks are advantageous because they are readily distinguished from
phosphors doped with other rare earth elements and secondary emission from fluorescent
dyes. As shown in Figure 2.1B, the intensity of the 538 nm luminescence changes with
pH because of changes in the dye absorbance spectrum. The intensity of peak at 613 nm,
however, was relatively constant and provides a reference. A calibration curve (Figure
2.1C) shows a dynamic range of pH 6-9 (note the pKa of the dye shifted upon adsorption
to the paper). The noise level between pH 7 and 8 was calculated to be 0.05 pH unit
(based on standard deviation and slope).
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Figure 2.4 Demonstration of imaging with X-ray limited resolution. Green X-ray
phosphors (Gd2O2S: Tb) and red phosphors (Gd2O2S: Eu) were deposited in a film with a
sharp interface between the red and green sections. The film was irradiated by a 2.0 mm
X-ray beam and a photograph was acquired at a series of sample positions (0.5 mm per
step). (A) Photo of phosphor film with X-ray beam excitation and room light. (B), (C),
(D) photo of luminescence (with room light blocked) as the sample was moved across the
red/green (Tb/Eu) phosphor interface. The positions of each figure were 5.5 mm, 6.5 mm,
7.5 mm. (E) Same image as (A) but with the film covered by a filter paper at a distance
of 10 mm. (F), (G), (H) corresponding to (B), (C), (D), respectively, but with the film
covered with a filter paper. The Luminescent image is blurred by the scattering in the
filter paper. Reprinted with permission from ref. 112. Copyright 2011 American
Chemical Society.
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Poor spatial resolution due to scattering is the most significant limitation of
conventional optical microscopy in thick tissue. To demonstrate the effect of scattering
upon resolution, we fabricated a two-component film with a region of Gd2O2S:Tb (green
luminescence), a second region of Gd2O2S:Eu (red luminescence), and a sharp interface
between the two regions. A 2 mm wide X-ray beam was used to excite optical
luminescence at different regions of the film before and after adding a piece of filter
paper above the sample to introduce scattering (See Figure 2.4). When the interface was
illuminated, the green and red phosphor films regions can be easily resolved before the
filter paper is added. After the paper is placed 1 cm above the sample, however, the
luminescence spot blurs and the color looks homogeneous. This color depends upon
which region is irradiated, thus scanning X-ray excited optical luminescence image is
convolved with the X-ray beam profile, thus the spatial resolution depends upon the beam
width. To image the phosphor interface at higher resolution through a scattering medium
we reduced the X-ray slit width to produce a narrower X-ray beam (260 μm width). For a
more realistic imaging scenario, we also replaced the filter paper with chicken breast
tissue.(Figure 2.5). The luminescence was imaged with a Nikon D90 digital camera as the
sample position was scanned relative to a fixed X-ray beam (Figure 2.5 C-F). The
phosphor film was then sandwiched between two 10 mm thick sections of chicken breast
and the experiment was repeated (Figure 2.5 B and G-J). Although the optical image
blurred to 8.5 mm after the phosphor film was inserted into the chicken breast, the color
indicated which region was under excitation. In our analysis, we treat the camera as a
single pixel detector and measure the total red, green, and blue pixel intensity in each
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picture using MATLAB scripts. The 90%/10% knife-edge resolution was 0.16 mm
without tissue, and 0.17 mm with tissue; the full knife-edge resolution including the most
tails was approximately 0.26 mm without tissue and 0.30 mm with tissue (Figure 2.6).
The small resolution increase in the tissue was likely due to imperfect sample alignment
and scattering of the incident X-rays in the tissue.

24

B

A

C

2mm

G

F

E

D

H

2mm

J

I

2mm

2mm

2mm

2mm

Figure 2.5 Example of imaging XEOL with X-ray limited resolution. Green X-ray
phosphors (Gd2O2S:Tb) and red phosphors (Gd2O2S:Eu) were deposited in a film with a
sharp interface between the red and green sections. The film was irradiated by a narrow
rectangular X-ray beam and a photograph was acquired at a series of sample positions (20
µm steps). (A) Setup schematic. (B) Setup photograph. (C) Photo of phosphor film with
X-ray beam excitation and room light. (D), (E), (F) Photo of luminescence (with room
light blocked) as the sample was moved across the red/green (Tb/Eu) phosphor interface.
(G) Same image as (C) but with the film inserted between two 10 mm thick sections of
chicken breast. (H), (I), (J) corresponding to (D), (E), (F), respectively, but with the film
inserted into chicken breast. The luminescent image is blurred by the scattering in the
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tissue from 0.26 mm to ~8.5 mm. The color ratio is shown as a function of position in
Figure 2.6. The positions of D, E, F and H, I, J in Figure 2.5 were 0.12 mm, 0.22 mm,
0.42 mm, respectively. Reprinted with permission from ref. 112. Copyright 2011

Intensity ratio of Red/Green

American Chemical Society.
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Figure 2.6 Ratio of red to green light intensity scanned at different positions (20 µm step
size) with/without 10 mm of tissue. It gives evidence of optical contrast at 0.30 mm
resolution through 10 mm chicken tissue. Reprinted with permission from ref. 112.
Copyright 2011 American Chemical Society.
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The technique has three advantages compared to conventional X-ray absorption
images.

First, indicator dyes provide chemical sensitivity. Second, phosphor

luminescence is a positive contrast mechanism with essentially no background, while
conventional X-ray transmission imaging detects small changes in the relatively large
background of transmitted X-rays, although contrast is enhanced using barium, gold
nanoparticles and other contrast agents.76 The positive contrast allows relatively noninvasive X-ray doses to be used. For phosphor films, doses are typically equal to or less
than that used in conventional X-ray imaging, except with blue light or deep tissue where
tissue absorbance can reduce total signal intensity. Third, multiple phosphors may be
used with distinguishable spectra for multiplexed imaging. It should be noted that
conventional X-ray images can be co-registered simultaneously with luminescence if Xray detectors are used to capture the transmitted X-rays while the optical detectors
measure luminescence.
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A visible/near-infrared point light source in an infinite tissue slab is attenuated by
a factor of 3 to 300 per cm of tissue depending on the type of tissue and wavelength
used.77 Spectral distortion remains a potential problem for our technique, although the use
of lanthanide phosphors with long lifetimes and narrow peaks can greatly mitigate the
problem. Spectral distortion is caused by effective attenuation in tissue which is
wavelength dependent according to the photon diffusion model:
))

(2)

Where μeff is the effective attenuation coefficient, μa is the absorption coefficient,
and μs’ is the reduced scattering coefficient.78-79 For example, although figure shows that
the spatial resolution was hardly affected by the 10 mm thick chicken breast, it is also
evident that the red/green ratio increased, especially for the Gd2O2S:Tb phosphor because
the 538 nm light is more rapidly attenuated than the 613 nm light. The methyl red
absorption causes a similar effect, thus the chicken breast tissue can cause interference if
not adjusted for. The tissue absorbance disproportionately affects the color ratio detected
by the digital camera because the camera filters are not tuned to the luminescence peaks.
However, the shift is considerably smaller between two nearby spectral peaks (e.g. 613
nm and 620 nm in the Gd2O2S:Tb and Gd2O2S:Eu phosphors, see Figure 2.7).

In

addition, there are several ways to address the spectral distortion such as a function of
time. Phosphorescence lifetime is alternative approaches which are not affected much by
scattering. Photoacoustic imaging is the only other technique that can provide highresolution visible imaging deep in tissue. Both X-ray phosphor imaging and
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photoaccoustic imaging avoid the problems of visible light scattering by converting
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Figure 2.7 Luminescent spectra of Gd2O2S:Tb and Gd2O2S:Eu phosphors. Reprinted with
permission from ref. 112. Copyright 2011 American Chemical Society.
Photoaccoustic microscopy measures acoustic waves generated by photothermal
expansion of tissue that absorbs a short pulse of intense light. The acoustic waves
generated are far less scattered than the optical waves and the image resolution is limited
by the acoustic transducer (45 µm lateral resolution and 3 mm imaging depth with a 50
MHz transducer) rather than the optical diffraction.80 The main limitations are that (a)
tissue scattering and absorption cause spectral distortions, and no lifetime discrimination
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techniques are available, (b) bone and metal can cause spatial distortions, (c)
photoacoustic microscopy requires a wavelength tunable high power pulsed laser, and (d)
samples must be immersed in an acoustic bath.
Conclusion
In summary, we developed a novel technique for in situ chemical imaging in
tissue. It combines chemical sensitivity from indicator dyes, demonstrated by the pH
sensor, with high spatial resolution, demonstrated by detecting a two-color X-ray
phosphor object with 0.30 mm resolution through 10 mm of chicken breast.

The

technique is sensitive because it is essentially background-free. The X-ray phosphors
with different emission spectra make them versatile sensing agents for colorimetric
detection. Future work involves using chemical indicator dyes for oxygen and other
analytes, developing lifetime-based chemical sensors which will not be affected by tissue
attenuation, using narrower X-ray beams and more sensitive detection optics for two
dimensional chemical imaging and tomography, and developing a portable imaging
system. Two dimensional chemical imaging will be especially useful for measuring
chemical changes on a surface, such as in situ detection of acidosis, hypoxia, and
hydroxyapatite degradation on implanted devices with bacterial colonies.62, 81
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Experimental Section
Materials
Methyl Red (C15H15N3O2) and filter paper (medium porosity) were purchased
from Fisher Scientific Co. (Fair Lawn, NJ, USA). pH buffers solution was purchased
from BDM Chemicals Ltd (Poole, Dorset, UK). Terbium-doped gadolinium oxysulfide
phosphor powder (Gd2O2S:Tb) and Europium doped Gadolinium oxysulfide (Gd2O2S:Eu)
were purchased from Phosphor Technology Ltd. (Stevenage, UK). Both Gd2O2S samples
contained microparticles that ranged in size from 2-15 µm with a nominal diameter of 8
µm. Carboxymethyl cellulose sodium was purchased from TCI (Tokyo, Japan). Cover
glass was purchased from Electron Microscopy Sciences (Fort Washington, PA, USA).
Deionized (DI) water and ethanol were purchased from EMD Chemicals Inc. (Gibbstown,
NJ, USA). Chicken breast was purchased from Coleman Natural Foods, Inc. (Golden, CO,
USA). All chemicals were used as received without further purification.
Preparation of phosphor film: 1.0 g Gd2O2S:Tb phosphor powder was mixed with 2
mL carboxymethyl cellulose sodium aqueous solution (0.5% w/v) and the entire solution
was applied to a cover glass (24×60 mm) and allowed to dry overnight. The film of
Gd2O2S:Tb and Gd2O2S:Eu phosphor coated on the same glass slide (25×75 mm) was
prepared in a similar way. 0.5 g Gd2O2S:Tb phosphor and 0.5 g Gd2O2S:Eu phosphor
were each drop-coated onto a separate cover glass (24×60 mm). These two phosphorcoated cover glasses were brought together and stuck to a glass microscope slide (25×75
mm) using double-sided tape.
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Preparation of methyl red dyed filter paper and pH measurement: A 12×100 mm
strip was prepared from filter paper of medium porosity and this strip was immersed in
600 µL ethanolic solution of methyl red (0.05% w/v) over night and dried thoroughly.
The ethanolic solution of methyl red (0.05% w/v) was prepared by adding 0.0010 g
methyl red powder into 2.00 ml ethanol. The 12×100 mm methyl red dyed strip then was
cut into a series of 12×8 mm pH-strips. After that, these pH-strips were placed onto a No.
0 coverslip covering the phosphor film as shown in Figure 2.2. A series of calibrated pH
buffer solution (pH 2.00-13.00) were then pipette onto each pH strip (10 µL). The stage
was moved so that each pH strip was irradiated and a series of five spectra were recorded
from different areas of the strip to determine the average and standard deviation of the
peak intensity ratio, as shown in Figure 2.1.
Instrumentation
To determine the phase of the samples, X-ray powder diffraction was performed
at 40 kV and 40 mA using a Rigaku Ultima IV X-ray diffractometer with CuKα radiation
at a scanning rate of 0.5º/min from 5º to 70º. The XRD patterns (Figure 2.3) were almost
identical.

They displayed narrow peaks indicative of particles with average crystal

domains > 90 nm in diameter.
For X-ray phosphor luminescence, the X-ray diffractometer was operated at 120º
with tube voltage of 40 kV and tube current of 50 mA. Luminescent spectra were
captured at room temperature with a FPC-400-0.22-1.5-UV fiber coupled photodiode
array spectrometer (BRC741E-02 BWTEK Inc, Newark, DE, USA).The stepper motor
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stage (MTS 50, Thorlabs, Inc. Newton, NJ, USA) was controlled by a program written in
Labview (National Instruments, Austin, TX, USA).
The luminescent images in Figure 2.4 were taken with a Nikon D90 digital
camera with a 67 mm diameter lens at 50 mm FL and a macro lens adaptor. All the
parameters of the camera were controlled by the software of Camera Control Pro2 (Nikon
Instruments Inc., Melville, NY, USA). The images without chicken breast (Figure 2.4 CG) were taken at ISO=200, shutter speed 1/4 s, f/5.6. The images with the phosphor
between two 10 mm thick sections of chicken breast (H-J) were taken at ISO=2000,
shutter speed 30 s, and aperture f/4.0. The increased exposure time, ISO and aperture
were necessary because the luminescence was dispersed over a wider area (~8.5 mm
instead of 0.26 mm), and the light and X-ray beam were attenuated by passing through
the tissue. A more sensitive detector (e.g. a photomultiplier tube or avalanche photodiode)
would require far shorter exposure times. All images were analyzed by Matlab R2008b.
In order to determine the X-ray beam width in Figure 2.4, we measured the ratio
of red/green intensity at the interface between the Gd2O2S:Tb and Gd2O2S:Eu phosphor
films. In addition to this intensity ratio we also measured absolute green intensity of a
phosphor film edge, which provided a similar beam width 0.26 mm as shown in Figure
2.6.
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CHAPTTER THREE

III. OPTICAL IMAGING IN TISSUE WITH X-RAY EXCITED LUMINESCENT
SENSORS
Introduction
Non-invasive biomedical imaging techniques are important for diagnosing
diseases studying disease processes.

Bright-field and fluorescence microscopy are

excellent techniques for chemical imaging in cells and thin tissue sections (<~200 µm)
because a wide range of fluorescent indicator dyes and nanoparticles are available that
provide high chemical sensitivity and selectivity. However, optical microscopy is of
limited utility in tissues deeper than 1 mm because almost all light is scattered causing
poor resolution.82-83

For tissue imaging other techniques are used such as X-ray

transmission and computed tomography (CT), ultrasound, and magnetic resonance
imaging (MRI).

These techniques provide high spatial resolution, but have limited

chemical sensitivity especially compared to optical techniques.84

Positron emission

tomography (PET),85 single photo positron emission computed tomography (SPECT),86
and Cerenkov radiation optical imaging87 are used to measure the in vivo distribution of
injected radioactive analytes. However, detection is limited in that the analyte must be
radiolabelled, the resolution is typically in millimeters, and there is only a relatively short
observation half-life (typically hours). Herein, we report a novel high-spatial resolution
imaging technique to measure optical absorption and detect chemical and physical
changes through thick tissue. The technique uses a narrow X-ray source to excite
luminescence from X-ray phosphors at a resolution limited by the X-ray beam-width. The
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phosphors serve as light sources with spectra and intensity that depend on local
absorption. Here we detect changes in luminescent intensity and spectrum due to
deposition of silver and gold nanoparticles onto the phosphors. We demonstrate imaging
of silver and gold patterns through 10 mm pork, and describe the mechanism of
luminescent attenuation.
Rare earth oxysulfide phosphors we used in this study have been widely used for
X-ray detectors due to their robustness and large quantum efficiency for X-ray to visible
light conversion.16, 18, 71, 88 Previous studies also showed rare earth ions such as Gd3+ and
Eu3+ are not highly toxic: LD50 for intravenous injection is 10-100mg/kg.72 For example,
chelated gadolinium MRI contrast agents are used in 20 million scans per year with an
average dose of 1.2 g/patient.73 The relatively low toxicity, chemical stability, and
resistance to photobeaching of rare earth oxysulfide phosphors make them ideal labels in
physiology conditions.74-75 They are used in X-ray excited optical luminescence (XEOL)
to map luminescent centers in semiconductor and rare-earth doped materials.89-90 The
principle can also be applied to detection of scintillation in cell labeling studies, for
example, Morrone used a form of scanning X-ray excited optical luminescence (XEOL)
to image optical emission of terbium labeled actin in a single cell and obtained a ~50 nm
resolution.49 However, other optical techniques are available for near-field imaging in the
absence of scattering,

91-92

and they did not apply their technique to the challenge of tissue

imaging where light scattering causes far more severe blurring (typically a ~10 mm point
spread for imaging through 10 mm of tissue). Adam and coworkers also proposed using
quantum dots for multiplexed cell labeling XEOL experiments using a table-top soft X-
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ray source.

50

Chen et al demonstrated energy transfer between X-ray excited phosphor

nanoparticles which caused X-ray excited photodynamic, therapy,

48, 65-66

but chemical

sensitivity and tissue imaging have not yet been shown. Recently, Pratx and co-workers
developed X-ray luminescence computed tomography (XLCT) which detects the
presence and location of X-ray phosphors in optically diffusive medium. Using 1-100
cGy of radiation dose, they achieved a spatial resolution of 1 mm through tissuemimicking material based on the selective excitation of subpicomolar of 50 nm phosphor
and optical detection of their luminescence.54 Pratx et al. recently showed that XLCT
could image the cross sectional distribution of microsize phosphor particles in 1 cm of an
agar tissue phantom.41 However, sensors for small chemical analyte in thick tissue have
not yet been explored. We demonstrate below that scanning XEOL can be used for highresolution imaging of local optical absorption through tissue.
Results and discussion
Imaging silver coating on X-ray phosphors in 1 cm tissue
High-resolution imaging of small features through tissue can be challenging.
Conventional X-ray imaging detects attenuation of transmitted X-ray photons, and
contrast requires a relatively large change in sample thickness or density. However,
XEOL is a positive contrast method which can detect lower concentrations of particles.
In addition, it is able to detect local absorption from indicator dyes and inorganic
materials, which enables high contrast and chemically specific imaging. For example,
gold has an X-ray absorption cross section of only a factor of ~1000× more than tissue,
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while the visible and NIR attenuation constant for a gold nanoparticle can be 108 times
larger than tissue allowing detection of nanometer thick gold films through a centimetre
of tissue.

Figure 3.1 (A) Schematic of the scanning X-ray excited optical luminescence (XEOLs)
absorption imaging technique. (B) Spectra of europium doped gadolinium oxysulfide
(Gd2O2S:Eu) film either uncoated or coated with 5 nm of vapour deposited silver. As a
control for whether silver contact was needed to attenuate XEOL, a glass slide coated
with 5nm of silver was also placed beneath the phosphor. Reproduced from Ref. 123 with
permission from the Royal Society of Chemistry.
Gold and silver nanoparticles are especially interesting materials for
spectrochemical sensors because they support a localized surface Plasmon resonance
(LSPR) mode, which provides intense sized- and shape-dependent optical absorption and
scattering spectra.93 They are used in a wide variety of chemical sensors based upon
refractive index changes as well as nanoparticle aggregation and disaggregation.94-95
Silver nanomaterials are also important antimicrobial agents and have been proposed as a
method to prevent and reduce implant associated infection.95-96 Methods to study the in
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situ silver dissolution rate and amount of silver coating remaining would thus be valuable
for evaluating antimicrobial efficacy and silver toxicity.
To demonstrate that a thin silver coating can be detected and imaged using
scanning tissue XEOL, we formed a monolayer of 8 µm Gd2O2S:Eu phosphor on tape,
and vapour-deposited a 5 nm thick silver film onto one side of the film. A physical mask
was employed so that one region was silver-coated and another left uncoated with a sharp
transition between the two regions. The silver coated film was irradiated with X-rays,
and the luminescence intensity was measured as shown in Figure 3.1. The intensity of
the silver-coated region was attenuated by 51% (at 617 nm) compared to the uncoated
region. Direct coating of the silver onto the phosphors was required: a control prepared
by placing a 5 nm silver-coated cover glass beneath the same slide of uncoated sample
resulted in an increase of intensity (5%) rather than reduction because of increased
reflection (see Figure 3.1 B).
The multiple narrow and intense spectral luminescence peaks of Gd2O2S:Eu are
advantageous because they are easily distinguished from secondary emission of
fluorescence from tissue. The strong red and near infrared luminescence peaks are only
weakly absorbed by tissue, although scattering greatly reduces resolution.
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Figure 3.2 (A) Schematic of the scanning X-ray excited optical luminescence (XEOLs)
absorption imaging technique in tissue. (B), (C) Intensity of red light scanned at different
positions with/without 10 mm of tissue. The full-width resolution is 1.7 mm through the
pork tissue (half-width is 0.85 mm). (D) Setup photograph of X-ray phosphor film under
10 mm pork. (E) Photograph of XEOL for the X-ray beam on a region of bare phosphor.
(F) Photograph of XEOL for a region of silver-coated phosphor. (G), (H) Same image as
(E), (F) but with the film under 10 mm thick section of pork, and with a larger exposure
time (30 s). Reproduced from Ref. 123 with permission from the Royal Society of
Chemistry.

To measure the spatial resolution of the scanning XEOL, a rectangular X-ray beam
(1.7 mm × 10 mm) irradiated the silver-coated phosphor sample through 1 cm of pork
tissue (Figure 3.2 A, D). The luminescent intensity was imaged with a Nikon D90 digital
camera as the sample position was scanned relative to a fixed X-ray beam. Although each
optical image showed a blurred 10 mm luminescence region due to scattering, the
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intensity and spectrum was modulated by local optical absorption. The total red, green,
and blue pixel intensity in each picture was analyzed in Matlab. The total intensity
collected as a function of position shows a clear knife-edge profile with a full-width of
just 1.7 mm through 10 mm of tissue (Figure 3.2C), limited by the X-ray beam width.
The slight broadening from 1.6 mm without the tissue is likely due to misalignment of the
phosphor film after placed under 1 cm pork, or a halo effect from scattering of soft Xrays.
Attenuation Mechanism
Having demonstrated high spatial-resolution imaging through tissue, we decided
to investigate the mechanism by which silver attenuated XEOL.

Three potential

mechanisms were initially considered. (a) Irreversible damage to the phosphor during
vapour deposition. This mechanism was ruled out after we showed that the intensity
recovered when the silver was dissolved in H2O2. (b) Energy transfer and dynamic
quenching of the Eu excited state by the silver nanoparticles. Silver and gold are known
to be efficient fluorescence quenchers97-98 and research by Chen and co-workers
demonstrated that nanophosphors are able to transfer their energy to generally less
efficient fluorescent dye.99-100 However, the phosphor particles had an average diameter
of 8 µm, and Forster energy transfer generally occurs over distances <10 nm and would
therefore only be efficient near the surface of the particle unless there is very long
lifetime and efficient energy diffusion to the surface. The hallmark of dynamic energy
transfer is a decrease in the excited state lifetime, which was measured below. (c) Local
absorption of light by the silver nanoparticles, i.e. the “inner filter effect.” Since the
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phosphor particles are significantly larger than the wavelength of light, we expected
geometric optics to largely apply. However, no direct absorption was possible because
the silver was deposited beneath the phosphors and the camera was imaging from above
(see Figure 3.1).
Based on the experiments outlined in Figure 3.1A, the likely mechanism is
indirect absorption due to attenuated total internal reflection. We also note that a 5 nm
silver film deposited on the top rather than bottom side of the phosphors reduced the
luminescence intensity by a total of 61% (at 617 nm) when viewed from above. (see
Figure 3.3). The intensity is reduced because the silver lies between the phosphor and the
camera and acts as a filter.
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Luminescence Lifetime
To determine if the silver caused dynamic quenching of the X-ray luminescence, we
measured the XEOL lifetime. An optical chopper was placed in front of the X-ray beam
and rotated at 250 Hz. A small amount (~3%) of X-ray energy passes through the 1 mm
thick Al chopper wheel even in the blocked state; however, a clear signal modulation is
evident (see Figure 3.4). The luminescence lifetime(s) was determined from the shape of
the curve. After a short transition period while the chopper shifts from not blocking the
X-ray beam to fully blocking the beam, the intensity is expected to decay exponentially
as follows:

I (t )  I 0e

t



where I(t) is the intensity at time, t, I0 is the intensity at time t=0, and τ is the
luminescence lifetime of the X-ray phosphor. A plot of ln(I) vs. t shows a linear curve
indicating a single lifetime over the observed timescale (Figure 3.4B, C). The lifetime of
phosphor luminescence from silver coated and uncoated samples is 0.387 ms and 0.390
ms, respectively. The lifetimes are similar to the nominal value quoted for the Gd2O2S:Eu
phosphor of no more than 0.45 ms.101 The unchanged lifetime between coated and
uncoated samples indicate that dynamic quenching was not responsible for attenuated
XEOL intensity, and absorption is the most likely alternative.
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Figure 3.4 (A) Luminescence responses resulting from X-ray pulse at 250 Hz measured
with a photomultiplier tube (B). (C) Plot of the log of the intensity vs. time after the
chopper blocked the X-ray beam.

Digitization noise is evident at low intensities.

Lifetimes for coated and uncoated samples are 0.387 ms, and 0.390 ms, respectively.
Reproduced from Ref. 123 with permission from the Royal Society of Chemistry.
Effect of silver film thickness on luminescent absorption
To determine if absorption was responsible for the reduced XEOL intensity, we
measured the XEOL intensity at various wavelengths as a function of silver film
thickness. We reasoned that if absorption were responsible, the signal would be smaller
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at wavelengths which are more strongly absorbed by silver nanoparticcles. The LSPR
absorption spectrum depends strongly on nanoparticle shape. Silver island film
nanoparticles are formed during vapour deposition, and as more silver is deposited the
particles become flatter until a continuous film is formed. Figure 3.5 shows SEM images
of progressively thicker silver film deposition. The particles change in shape from small
and approximately spherical to larger flatter particle shapes and eventually continuous
films with some surface roughness. For particles deposited upon a flat glass surface, this
change in shape leads to a larger transverse LSPR resonance and a red-shift in extinction
spectrum as shown in Figure 3.6A. When the silver is deposited upon the angled and
faceted surfaces of the phosphor microparticles the extinction spectrum (Figure 3.6B) is
blue-shifted compared with the spectrum on flat glass due to changes in nanoparticle
orientation and shape.
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Figure 3.5 SEM images of (A) phosphor particles (B)-(F) Close up view of the phosphor
surface coated with different thicknesses of silver: (B) 0 nm silver, (C) 3 nm, (D) 5 nm,
(E) 10 nm, (f) 20 nm. Reproduced from Ref. 123 with permission from the Royal Society
of Chemistry.
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Figure 3.6 (A) Extinction spectra of silver film on cover glass (cover glass was used as
the reference). All spectra are normalized to Amax=1. The real Amax for 1, 3, 5, 10, 20, 30,
40, 50, 60 nm are 0.02, 0.17, 0.31, 0.59, 0.84, 1.25, 1.60, 1.95, and 2.23, respectively. (B)
Extinction spectra of silver film on phosphor particles (phosphor film coated cover glass
was used as the reference). All spectra are normalized to Amax=1. The real Amax for 1, 3,
5, 10, 20, 30, 40, 50, 60 nm are 0.02, 0.09, 0.14, 0.51, 0.55, 0.69, 0.83, 0.87, and 0.90,
respectively. Inset shows a photograph of the silver coated phosphor film. Reproduced
from Ref. 123 with permission from the Royal Society of Chemistry.
The XEOL spectrum depended on the silver deposition thickness (see Figure
3.7A). The variation of relative luminescence lost for film from 1 nm to 10 nm can be
explained by the size and shape-dependent absorption properties of the nanparticles in the
silver island film. (See Figure 3.6). In general, the luminescent attenuation order for each
peak is 588 nm> 608 nm> 617 nm> 697 nm which is consistent with the extinction
spectra of silver film on phosphor particles (Figure 3.6B). For films thicker than 10 nm
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(more than the optical penetration depth of silver), the silver largely behaves as a lossy
mirror, and the attenuation effect saturates.

Figure 3.7 (A) Luminescent spectra of Gd2O2S:Eu phosphor coated with different
thickness of silver film. (B) Relative luminescence loss ((Iuncoated-Icoated)/Iuncoated×100%)
varies with different thickness of silver. Reproduced from Ref. 123 with permission from
the Royal Society of Chemistry.
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Figure 3.8 (A) Luminescent intensity at 617 nm in air and oil. (B) Relative luminescent
intensity loss ((Iuncoated-Icoated)/Iuncoated×100%) in air and oil. Reproduced from Ref. 123
with permission from the Royal Society of Chemistry.
The above experiments indicated that absorption was the most likely explanation
for the silver attenuation because the attenuation showed a spectra dependence that was
consistent with the silver nanoparticle extinction spectrum. However, since the silver
coating was beneath the phosphors, and the camera and spectrometer detected light
emitted through the top of the particles, the silver must absorb light that would otherwise
be reflected from the bottom of the particles (e.g. due to refractive index mismatches).
The refractive index of Gd2O2S:Eu is between 2.1 and 2.3 RIU.102 Assuming an
intermediate refractive index of 2.2, the phosphor/air interface has a critical angle of 27º
which corresponds to reflection from a solid angle of 1.82π2, or 91% of an incident
angles. In addition, 14% of normally incident light reflected at the Gd2O2S/air interface.
For comparison, the critical angle for the phosphor/double-sided sticky tape interface is
42º, assuming a refractive index of 1.5 for the tape, this corresponds to reflection from a
solid angle of 1.54π2 or 77% of incident angles; the normal reflection coefficient is 3.6%.
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Therefore, most of the light is reflected once or more and most of light is emitted
through the top of phosphor/tape interface. This hypothesis explains why a silver coating
below affects the light above. It also explains why placing a mirror below the phosphors
increases the luminescence, but by less than a factor of 2 (see Figure 3.1B). To further
test this hypothesis, we incubated the phosphor film in microscope immersion oil with a
refractive index of 1.518 RIU (see Figure 3.8). The overall intensity of light collected
through the top of the film decreased, consistent with a decrease in reflection from the
bottom surface (Figure 3.8A). In addition, the relative effect of attenuation from silver
absorption was less significant after adding oil which is consistent with a reduced amount
of internal reflection (Figure 3.8B). These results support the internal reflection
hypothesis. Internal reflection increases the effective absorption path length and enhances
local absorption from nanoparticles and dyes on the surface which is adventurous for
measuring small changes in absorbance. Furthermore, the particles can be designed to
detect changes in local refractive index, a feature which can be employed to observe
label-free protein binding and polymer degradation.
Dissolution of silver nano-film in H2O2
Hydrogen peroxide plays a significant role in cell biology. It is a messenger
molecule for a wide variety of processes including cell development and programmed
cell death.103-104 It is produced by macrophages to destroy pathogens and also serves as an
inflammatory marker. H2O2 is also produced in many aerobic processes and enzymatic
reactions. These reactions are often used in electrochemical analysis, for example glucose
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is routinely detected by electrochemically measuring the amount of H2O2 produced in the
presence of glucose oxidase105 and peroxidise enzymes.
Silver is an important antimicrobrial agent which is found in a wide variety of
cosmetics and textiles, and has been proposed as an antimicrobial agent for implanted
medical devices.106-107 Recently there have been several studies of the reaction rate of Ag
with H2O2 in different pH and temperature conditions. The overall reaction is shown
below.108-109 The reaction is sensitive to concentrations of salts and enzyme, for example
Liu et al. showed an increase in reaction rate with decrease in pH, and proposed a
hydroxyl radical intermediate (OH•),108 while Ho et al. found an increase in reaction rate
with increasing pH (due to reaction of HO2-) and no hydroxyl intermediate.109
technique capable of measuring in situ silver dissolution would therefore be useful.
2Ag (s) + H2O2 → 2Ag+(aq) + 2OH- (see ref.27, 28)
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Figure 3.9 Luminescent intensity at 617 nm as a function of time during silver dissolution
in 1 mM H2O2. Reproduced from Ref. 123 with permission from the Royal Society of
Chemistry.
To study the dissolution of a silver island film in H2O2, 5 nm of silver was vapour
deposited upon a Gd2O2S:Eu phosphor film, and the luminescent spectra were recorded
in time during dissolution in a 1 mM H2O2 aqueous solution. The dissolution of the silver
was indicated by the increase in luminescent intensity. As shown in Figure 3.9, after the
silver film dissolved in H2O2, the luminescent intensity recovered to normal intensity
within experimental error from sample to sample variation.

Although 1 mM H2O2

concentration is a very high level for physiological conditions,110-111 the dissolution was
relatively rapid (30 min), compared to a few weeks in physiological conditions. For
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example, assuming that rate is proportional to concentration,108-109 30 minutes at 1 mM
corresponds to a 7 µM concentration dissolving in 3 days or 700 nM over one month. In
addition, the physiological rate may be different due to changes in pH, increased
temperature (37 ºC instead of 23 ºC), extracellular components including chloride ions
and metal binding enzymes, adsorption of protective proteins, and mechanical abrasion.
The ability to tune the silver thickness and location presents a promising method to study
dissolution kinetics in vivo.
Imaging silver dissolution through tissue
To detect low concentrations of H2O2 (1 mM) in thick tissue with high spatial
resolution, we use a narrow X-ray beam to excite the phosphor film. We selected a 5 nm
thick silver film on Gd2O2S:Eu since the luminescent reduction is enough to distinguish
(Figure 3.8A) and the small particle size reduces the time required to dissolve the silver
(Figure 3.9). The silver coated phosphor film was incubated in 1 mM H2O2 solution (100
μl of 30% (w/w %) H2O2 solution was added in 1000 ml DI water (pH 5.5)) at room
temperature for 3h. We also deposited a 5 nm thick strip of gold as a chemically inert
control. Figure 3.10 shows that the 5 nm gold film reduces the intensity more than the 5
nm silver film. This intensity difference and the stability of gold in physiological
conditions make the gold film a good reference and fiduciary marker.
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Figure 3.10 Luminescent spectra of phosphor film with 5 nm of silver and 5 nm of gold
film. Reproduced from Ref. 123 with permission from the Royal Society of Chemistry.

In order to image local changes in silver absorbance, we masked some regions of a
silver film with double sided sticky tape prior to exposure to 1 mM H2O2. Figure 3.11A is
a photograph of a phosphor film coated by a strip of silver 5 nm thick and 7.4 mm wide
as well as a strip of vapour-deposited gold, 5 nm thick and 2.3 mm wide. Two regions of
the silver film were masked with thin strips of tape so that only a strip in the center was
unprotected. The sample was plasma etched for 5 min in air plasma to make all regions
hydrophilic. The sample was then incubated in H2O2 for 3 hr to dissolve the unprotected
section of silver film (See Figure 3.11D). A one dimensional XEOL image was acquired
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from the film before and after silver dissolution, and the XEOL was performed with and
without placing a 1 cm thick section of pork tissue above the film. The H2O2 etched area
can be clearly identified by the increased luminescence, while it can be distinguished
from the gold coated region with lower XEOL intensity. The gold coated region was
unaffected by H2O2 providing a control strip. Most importantly, the resolution of the
XEOL scan was hardly affected by the 1 cm of pork demonstrating that high resolution
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Figure 3.11 (A), (D) Images of gold and silver coated phosphor film before and after
H2O2 etching. (B), (E) Intensity of red light scanned at different positions with/without 10
mm of tissue before H2O2 etching. (C), (F) Intensity of red light scanned at different
positions with/without 10 mm of tissue after H2O2 etching. The resolution through 10 mm
tissue is 1.7 mm. Reproduced from Ref. 123 with permission from the Royal Society of
Chemistry.
Conclusion
We have extended the XEOL technique to tissue imaging where it offers a
combination of high spatial resolution (limited by the X-ray beam width) and high
sensitivity optical detection. The high spatial resolution is competitive with conventional
X-ray imaging but offers the ability to detect nanometer thick metal coatings and small
changes in local absorption near indicator particles. Proof-of-principle involved detecting
silver and gold nanoparticle patterns through 10 mm of pork as well as monitoring silver
dissolution in H2O2, but the technique is general to a wide variety of indicator dyes and
nanoparticle labels. Interestingly, the high refractive index of the Gd2O2S phosphor
increased the effective attenuation path length around the particle and also provided a
method for label free detection of changes in local refractive index.
In future, the instrumentation can be enhanced using a narrower X-ray beam for
higher spatial resolution imaging and using a multiple axis stage for two and three
dimensional imaging. In addition, higher sensitivity and more rapid signal acquisition
can be realized with a modulated X-ray source and a photomultiplier tube with lock-in
signal amplification (see Figure 3.4). An important application will be the non-invasive
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detection of localized implant associated infection. We plan to use the technique to study
bacterial products and inflammation markers, including hydrogen peroxide, oxygen,
pH,112 quorum sensing molecules, and bacterial stains. Multiple analytes may be detected
on spatially patterned sensors, as shown above using silver and gold nanoparticle patterns
(see Figure 3.11). Alternatively, spectrally multiplexed sensing is possible using multiple
rare-earth doped phosphors with narrow spectral peaks. Relatively robust and long-lived
sensors can be developed using inorganic materials, such as silver nanoparticles and
hydroxyapatite, to monitor in situ chemical reactions through associated changes in local
absorption and refractive index. Overall, scanning XEOL provides new capabilities for
chemical analysis in tissue and turbid media.
Experimental Section
Materials
Hydrogen peroxide aqueous solution (30% w/w) was purchased from BDH
Chemicals Ltd (Poole, Dorset, UK). Europium doped Gadolinium oxysulfide
(Gd2O2S:Eu) was purchased from Phosphor Technology Ltd. (Stevenage, UK) and it
contained microparticles that ranged in size from 2~15 µm with a nominal diameter of
8 µm. Silver wire (>99.99%, 1 mm diam.) and gold wire (99.999%, 1 mm diam.)
were purchased from Sigma-Aldrich (St Louis, MO, USA). Double sided tape (3M
666, 1×1296 Inch) was purchased from 3M Company (St. Paul, MN, USA). Cover
glass (No. 0, 24×60 mm) was purchased from Electron Microscopy Sciences (Fort
Washington, PA, USA). Immersion oil was purchased from Leica Microsystems
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(Wetzlar, Germany). Deionized (DI) water was purchased from EMD Chemicals Inc.
(Gibbstown, NJ, USA). Pork was purchased from Ingles Market, Inc. (Asheville, NC,
USA). Reynolds Wrap Quality Aluminum Foil was purchased from Consumer
Products Division of Reynolds Metal (Richmond, VA, USA). All chemicals were
used as received without further purification.
Preparation of the Gd2O2S:Eu phosphor film and coated with silver and gold nanofilm
A 24×60 mm cover glass was covered with double sided tape. A single layer of
particles was attached to the surface of double-sided tapped by spreading 0.5 g europium
doped gadolinium oxysulfide (Gd2O2S:Eu) powder on top of the tape. Excess particles
were removed by rinsing in DI water, followed by drying at room temperature for 2hr.
The sample was plasma etched for 5 min in a Harrick plasma etcher at media power in air
plasma to make the surface hydrophilic. Finally the sample was coated with silver or gold
using thermal vapour deposition.
Nano-film of silver and gold coating and dissolution of the silver in hydrogen
peroxide solution
The Gd2O2S:Eu film was coated with a thin layer of gold or silver. The metal was
deposited using thermal vapour deposition (Auto 360 vacuum coater/thermal evaporator,
Edwards, West Sussex, UK) under high vacuum (< 5 × 10−6 Torr). The thickness of the
metal was controlled using a shutter and measured with a quartz crystal microbalance. In
order to study the rate of silver dissolution in H2O2, a Gd2O2S:Eu film was prepared with
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a 5 nm thick average coating of silver. The film was then incubated in 1 mM H2O2 and
the sample was taken out for luminescent spectra in every ten minutes. In order to
selectively dissolve only a portion of silver in H2O2, a 5 nm silver film was masked with
two strips of tape leaving an unmasked region between the two strips. The sample was
then incubated in 1 mM H2O2 for 3 hr to dissolve the unmasked region.
Instrumentation
An X-ray diffractometer (Rigaku; MiniFlex, Cu Kα ) was used as an X-ray source.
For X-ray phosphor luminescence, the X-ray diffractometer was operated with tube
voltage of 30 kV and tube current of 15 mA. The sample was mounted on a stepper motor
stage (MTS 50, Thorlabs, Inc., Newton, NJ, USA) which was controlled by a program
written in Labview (National Instruments, Austin, TX, USA). To measure lifetime, the
X-ray irradiation was modulated by an optical beam chopper equipped with a 1 mm thick
aluminium chopper wheel (Stanford Research Systems, model SR540, CA). The intensity
of the emitted light was measured with a PMT (R955, Hamamatsu Photonics, Japan)
connected to Tektronix TDX 2004B Oscilloscope. The signal acquisition was triggered
off of the chopper wheel photodiode. Data was transferred from the oscilloscope using an
interactive measurement software v1.2 (NI SignalExpress Tektronix edition). The PMT
was placed over a 0.5 cm thick piece of glass to block the small amount of scattered Xray photons while passing the visible luminescence. Scanning electron microscopy
(SEM) was performed on a SU6600 microscope operated at 20 kV.

Luminescent and

extinction spectra were acquired at room temperature with a FPC-400-0.22-1.5-UV fiber
(Thor Labs) coupled photodiode array spectrometer (BRC741E-02 BWTEK Inc, Newark,
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DE, USA). Luminescent images were taken with a Nikon D90 digital camera with a 67
mm diameter lens at 50 mm FL and a macro lens adaptor. To increase the captured
luminescence, a 3×16 cm piece of aluminum foil was placed beneath the phosphor film.
All the parameters of the camera were controlled by the software of Camera Control Pro2
(Nikon Instruments Inc., Melville, NY, USA). All images were analyzed using Matlab
R2009b.
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CHAPTTER FOUR

IV.
MONITORING
PH-TRIGGERED
DRUG
RELEASE
FROM
RADIOLUMINESCENT NANOCAPSULES WITH X-RAY EXCITED OPTICAL
LUMINESCENCE
Introduction
Doxorubicin (DOX) is a chemotherapy drug used to treat a wide range of cancers.
However, its serious adverse effects such as suppression of hemaropoiesis,
gastrointestinal and cardiac toxicity limit its applications.113-114 It is crucial to control the
concentration of doxorubicin specifically in the blood circulation, normal tissues, and
tumor tissues. Unfortunately, DOX clears rapidly from circulation (circulation half-life of
< 5 min)115 which makes it difficult to specifically target tumor cells using free drug. A
pH- responsive controlled system for DOX could address this issue by releasing drugs
into the blood only gradually, but rapidly release drugs after endocytosis in acidic tumor
lysosomes and endosomes. The particles could be targeted to tumors via enhanced
permeability and retention (EPR) effect and by functionalizing the nanoparticle surface
with appropriate antibodies or other targeting molecules. In 2005, Lee et al. reported pHsensitive micelles as carriers for DOX to enhanced tumor specificity and endosome
disruption property on the carrier.116-117 Recently, mesoporous silica has gained attention
as drug storage and release hosts due to their textural properties and easily modified
surface.118-121 Zhu and co-workers reported pH-controlled delivery of DOX to cancer
cells based on small mesoporous carbon nanospheres. In our previous work, a ratiometric
pH sensor based on the ratio of certain radioluminesence peaks of terbium doped
gadolinium oxysulfide (Gd2O2S:Tb) was developed.112 The ratio of luminescent spectral
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peaks is independent of the luminescence intensity which provides a promising method to
detect chemicals in tissue with high spatial resolution with a narrow scanning X-ray beam
and selectively exiting the phosphor film by taking advantage of the excellent penetration
of X-ray beam in tissue and wide range of availability of X-ray phosphors.122 Xing group
and we found that changes in spectrum and intensity can be imaged through tissue at a
resolution dictated by the X-ray beam,54-55, 123 and we have demonstrated submilimeter
imaging through 1 cm of chicken breast.112, 124 We also demonstrated that the XEOL
spectrum of hollow Gd2O3:Eu nanoparticles is greatly reduced by the presence of an iron
oxide core,125 and the luminescence of solid Gd2O2S:Eu particles is modulated by the
absorption spectrum of silver nanoparticles on the phosphor surface.123 Based upon these
results, we hypothesized that we could monitor release of dyes and optically absorbing
drugs from the core of nanocapsules.
In this work, we synthesize rare-earth (Tb, Eu) doped Gd2O2S based
radioluminescent capsules as a drug nanocarrier and drug release monitor. Compared
with gadolinium oxide doped with Eu, Tb and Eu doped gadolinium oxysulfide possesses
higher photo conversion efficiency (60,000 visible photons/MeV for Gd2O2S:Tb, and
Gd2O2S:Eu,

40,000

visible

photons/MeV

for

Gd2O3:Eu).124

Their

bright

radioluminescence (Figure 4.1) can be used to track the delivered drug (DOX) and
monitor the drug release process. Meanwhile, these capsules serve as good T2-weighted
MRI contrast agent which can be used as a complementary imaging mode for X-ray
functional imaging.126
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Results and discussion
Particle shape plays a crucial role in the application of drug delivery systems.127-128
Some previous studies on particles with high aspect ratio (e. g. nanorod, nanorice)
showed that those particles (> 500 nm in length) with high aspect ratio have slower
clearance rate compared with particles with low aspect ratio (e.g. spherical particles) in
the application of drug delivery systems.129-130 To demonstrate the shape effect on the
clearance rate for the future study, we chose ellipsoidal hollow silica nanorice as
templates to synthesize monodispersed ellipsoidal nanocapsules. In addition, by varying
the synthesis condition of template,131-133 the length of these nanocapsules are can be
tuned from 20 nm to 600 nm and the aspect ratio can be adjusted from spheres to prolate
spheroids. In order to obtain monodispersed silica nanoshells, as shown in Figure 4.2,
monodispersed hematite nanorice is first prepared, then treated through a modified Stöber
procedure to form a thin silica shell. Finally the hematite core was removed by etching in
0.5 M oxalic acid for 17 h. The uniform and negatively charged silica shell were then
coated with a layer of positive charged Gd2O(CO3)2•H2O doped with terbium (Tb3+, 2.4%
mol) or europium (Eu3+, 5.1% mol) through a homogeneous precipitation method from
gadolinium, europium nitrate. This method employs an electrostatic interaction between
negative charged silica shell and positive charged radioluminescent shell.125 After heat
treatment at 600 °C for 1 h, the amorphous Gd2O(CO3)2•H2O layer transformed into
Gd2O3. The above product was treated by sulphur gas with argon flow at 900 °C for 1h to
convert the Gd2O3 to Gd2O2S. The obtained nanoparticles was re-heated at 400 °C in the
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air for 1h and incubated in boiling water for 2 h to remove the residue of sulphur and
gadolinium sulphide.
TEM images in Figure 4.3A show monodispersed spindle-shaped iron oxide seeds.
Figure 4.3B represents the intact silica shell after the iron oxide core was removed by
dissolving in oxalic acid. The SEM image in Figure 4.3C and narrow size distribution in
Figure 4.3D indicate the monondispersed nanocapsules were obtained successfully with
an average length of 420 +/-20 nm and width of 130 nm +/-15 nm. The nanocapsules
possess a 10 nm thick inner silica shell and a 25 nm thick outer Gd2O2S:Tb
radioluminescent shell (Figure 4.3F) with porous morphology (Figure 4.3E, F and Figure
4.4,). The pores are irregular in shape, with an average diameter of (8.5 +/- 2 nm). These
visible pores in the shell (Gd2O2S:Tb) of the nanocapsules likely facilitate drug loading
and releasing. Crystal structure and composition of these nanocapsules were
characterized by powder X-ray diffraction (XRD) and the host is shown as hexagonal
phase of Gd2O2S according to the data of JCPDS card no. 26-1422 (Figure 4.5).
Gd2O2S:Eu with similar aspect ratio were also synthesized by the same silica
nanotemplate (Figure 4.6). The tunable size range and the morphology make these
nanocapsules promising as drug carriers. In order to apply these nanocapsules in
biological applications, the stability of the nanocapsules was tested in 0.3 % (v%) acetic
acid (pH ~3.0). The SEM images in Figure 4.7 show no discernible dissolution indicating
that the nanocapsules are very stable under pH 3 at 37 °C even after 24 hr. The cell
viability of our X-ray phosphors on MCF-7 breast cancer cells is also tested and it’s
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shown that cell viability is greater than 90% when the concentration of Gd2O2S:Tb and
Gd2O2S:Eu is as high as 250 µg/ml, after incubation for 24 h (Figure 4.8).
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Figure 4.1 X-ray luminescence of (A) Gd2O2S:Tb and Gd2O3:Tb nanocapsules, inserted
figure shows the spectrum of Gd2O3:Tb in high magnification, (B) Gd2O2S:Eu and
Gd2O3:Eu nanocapsules. Photograph of Gd2O2S:Tb, Gd2O3:Tb, Gd2O2S:Eu, and
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Gd2O3:Eu under X-ray (C). Reprinted with permission from ref. 126. Copyright 2012
American Chemical Society

Figure 4.2 Schematic illustration of the synthesis of radioluminescent nanocapsules.
Reprinted with permission from ref. 126. Copyright 2012 American Chemical Society.
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Figure 4.3 (A) TEM image of monodispersed iron oxide seeds, (B) TEM image of hollow
silica shell after removing iron oxide core, (C) SEM image of monodispersed
radioluminescent nanocapsule (Gd2O2S:Tb (Tb/Gd=2.4% mol), (D) Size distribution of
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the nanocapsules, (E) High magnification SEM image of nanocapsule, (F) TEM image of
the nanocapsule, (G) High magnification SEM image of surface of a nanocapsule, (H)
pore size distribution from 100 nanocapsules. Reprinted with permission from ref. 126.
Copyright 2012 American Chemical Society.

100 nm
Figure 4.4 SEM image showing the porous and hollow nanocapsules (Gd2O2S:Tb).
Reprinted with permission from ref. 126. Copyright 2012 American Chemical Society.
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Figure 4.5 XRD patterns of (A) Gd2O(CO3)2•H2O:Tb, (B) Gd2O3:Tb, (C) Gd2O2S:Tb.
Reprinted with permission from ref. 126. Copyright 2012 American Chemical Society

69

A

B

1 µm

100 nm

Particle number (%)

C

40

30

20

10

0
200

250

300

350

400

450

500

550

Length of nanocapsules (nm)

600

Figure 4.6 SEM (A) and TEM (B) images of nanocapsule (Gd2O2S:Eu, Eu/Gd=5.1%
mol), (C) size distribution of nanocapsules (Gd2O2S:Eu). Reprinted with permission from
ref. 126. Copyright 2012 American Chemical Society.
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Figure 4.7 XRD patterns of (A) Gd2O(CO3)2•H2O:Eu, (B) Gd2O3:Eu, (C) Gd2O2S:Eu.
Reprinted with permission from ref. 126. Copyright 2012 American Chemical Society.
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multilayers coated nanocapsules (Gd2O2S:Tb). Reprinted with permission from ref. 126.
Copyright 2012 American Chemical Society.

The radioluminescence spectra of nanocapsules (Gd2O2S:Tb, Eu) are presented in
Figure 4.9. The radioluminescence mechanism involves the generation of electron-hole
pairs in the host lattice following X-ray absorption. These electron-hole pairs then excite
Tb3+ and Eu3+ centers which emit visible and near infrared light. The conversion
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efficiency is 60,000-70,000 visible photons/MeV X-ray photon in bulk Gd2O2S:Eu,
corresponding to an energy efficiency of 15%.22, 36, 134 The narrow luminescent peaks of
Gd2O2S:Tb are attributed to the transitions from the 5D4 excited-state to the 7FJ (J=6, 5, 4,
3, 2, 1, 0) ground states of the Tb3+ ion. The 5D47F5 transition at 544 nm is the most
prominent group. The 5D0,17FJ (J=0, 1, 2, 4) transition lines of the Eu3+ ions generate
the intense peak at 590, 612, 620, 720 nm. The strongest red emission which splits into
two peaks at 621 and 612 nm arises from the forced electric-dipole 5D07F2 transitions of
the Eu3+ ions. These nanocapsules displayed similar fluorescence spectra under blue
excitation light (460-495 nm) (Figure 4.10). However, blue light does not penetrate as
deeply into tissue as X-rays, and unlike X-rays, does not stay collimated or focused
which dramatically reduces image resolution.
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Figure 4.9 X-ray luminescence of nanocapsules. (A) Gd2O2S:Tb, (B) Gd2O2S:Eu.
Reprinted with permission from ref. 126. Copyright 2012 American Chemical Society.
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Figure 4.10 Fluorescence spectra of nanocapsules (Gd2O2S:Tb and Gd2O2S:Eu) excited
by 460 to 495 nm light. Reprinted with permission from ref. 126. Copyright 2012
American Chemical Society.
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Figure 4.11 (A) schematic illustration of the synthesis of DOX@Gd2O2S:Tb@PSS/PAH
and pH-responsive release of DOX. Low magnification (B) and high magnification (C)
TEM image of DOX@Gd2O2S:Tb@PSS/PAH. Reprinted with permission from ref. 126.
Copyright 2012 American Chemical Society.
Styrenesulfonate sodium (PSS) and poly(allylamine hydrochloride) (PAH) are
widely used polyelectrolytes in pH-controlled release systems.135-138 In order to create a
stimuli-responsive system for DOX, our X-ray luminescent nanocapsules coated with
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eight layers of negative charged PSS and seven layers of positive charged PAH to
encapsulate DOX with layer by layer assembly (Figure 4.11; the particle is denoted as
DOX@Gd2O2S:Tb@PSS/PAH). Due to the surface of our nanocapsules are positive
charged (+14.9 mV, Figure 4.12), the first layer of polyelectrolyte coated on
nanocapsules is PSS. After the layer by layer coating, the nanocapsules are coated by an
average of 30 nm thick polyelectrolyte with a layer of PSS on the surface. Cell viability
test indicates that the empty Gd2O2S:Tb nanocapsules coated with PSS/PAH multilayers
show no significant toxicity to a concentration of at least 250 µg/ml, the highest
concentration measured (Figure 4.8). In order to demonstrate the DOX is loaded into the
nanocapsules, nanocapsules filled with solid core were synthesized as a control by using
the silica coated hematite instead of hollow silica shells as the template. The same DOX
loading and polyelectrolyte coating were employed to the nanocapsules with a solid core
(iron sulfide). From the released DOX from these solid particles, we calculate that the
hollow particles release approximately 20× more DOX than the solid-core particles,
indicating that most of the DOX is stored in the core of the hollow particles (Figure 4.13).
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Figure 4.12 Zeta potential of Gd2O2S:Tb nanocapsules. Reprinted with permission from
ref. 126. Copyright 2012 American Chemical Society.
To study the release rate at normal physiological pH and in acidic cancer
environments, we measured the release rate in pH 7.4 PBS and 5.0, respectively. The
cumulative release profile of doxorubicin from these nanocapsules is pH-dependent
(Figure 4.14). The drug release is enhanced at pH 5.0 which is applicable for cancer
therapy due to the low pH environment in tumor endosomes. Based upon exponential
fitting to the HPLC release curve, the release rate time constant was estimated to be ~ 36
days at pH 7.4, and 21 hr at pH 5.0. From the released DOX at pH 5.0 after 48 h, the
encapsulated DOX in DOX@Gd2O2S:Tb@PSS/PAH was over 5% by weight. The
luminescence peak ratio at 544 nm and 620 nm is used to track the release of DOX
(Figure 4.14B). The release rate time constant was estimated to be ~ 7 days at pH 7.4,
and 4 hr at pH 5.0. The radioluminescence peak ratio is shown to be very sensitive to the
release of DOX in the first 10 hr.
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Figure 4.13 (A) PSS/PAH coated multilayers of nanocapsules with solid core, (B)
absorbance of cumulative DOX released of hollow nanocapsules and nanocapluses with
solid core at pH 2. Reprinted with permission from ref. 126. Copyright 2012 American
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at pH 5.0 and 7.4, (B) peak ratio of real time radioluminescence detection at 544 and 620
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nm as a function time in pH 5.0 and pH 7.4. The data fits to a single exponential.
Reprinted with permission from ref. 126. Copyright 2012 American Chemical Society.
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Figure 4.15 (A) Absorption of DOX (0.05 mg/ml at pH 5.0 and 7.4) and
radioluminescence of Gd2O2S:Tb@PSS/PAH, (B) real-time radioluminescent spectra of
DOX@Gd2O2S:Tb@PSS/PAH at pH 5.0. Reprinted with permission from ref. 126.
Copyright 2012 American Chemical Society.

Our pH-responsive controlled release system is also able to monitor the release
process of DOX at different pH by detecting the radioluminescence of Gd2O2S:Tb
nanocapsules (Figure 4.15B). At pH 5.0 and 7.4, DOX has a similar broad absorption of
light from 350 to 600 nm which overlaps with some of the XEOL peaks of Gd2O2S:Tb
(Figure 4.15A). Figure 4.15B shows the intensity ratio of X-ray luminescence at 544 nm
and 620 nm increases with the release of doxorubicin because local luminescence
absorption by DOX decreases when DOX is released. We observed the similar
luminescent increase of nanoparticle with iron oxide as a core when the iron oxide are
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partially dissolved.125 The peak intensity ratio reaches a maximum value when the DOX
concentration in the particles is in equibilibrium with the solution concentration.
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Figure 4.16 (A) Photograph of MCF-7 breast cancer cells with and without internalized
nanocapsules (Gd2O2S:Eu) under room light and X-ray irradiation.

Transmitted

differential intereference contrast microscopy (B) and fluorescence image (C) of MCF-7
cells with internalized nanocapsules (Gd2O2S:Eu), (D) Merged image of (B) and (C).
Reprinted with permission from ref. 126. Copyright 2012 American Chemical Society.
In order to examine the uptake of these nanocapsules by cancer cells,
nanocapsules doped with europium (Gd2O2S:Eu) were incubated with MCF-7 cancer cell
and washed multiple times to eliminate nanocapsules from the cell culture media. The
internalized nanocapsules were brightly luminescent under X-ray radiation (Figure.
4.16A). The bright fluorescence signal of nanocapsules is very useful in drug localization
and cell labeling. Figure 4.16C shows the fluorescence signal of the Gd2O2S:Eu
nanocapsules in MCF-7 cancer cell after multiple washing step to eliminate nanocapsules
from the cell culture media.
To demonstrate that the nanoparticle XEOL can be imaged in vivo using a IVIS
Lumina-XR Imaging System (Caliper Life Sciences, Hopkinton, MA, US) during
irradiation with miniature X-ray source (Amptek Mini X-ray tube, Ag target, Amptek
Inc. MA, USA), 200 µL of 1 mg/mL Gd2O2S:Eu nanocapsules coated with PSS/PAH
multilayers were inject into a mouse tail vein. The effective nanocapsule concentration in
the mouse is about 133 μg/ml (the blood volume of a mouse is around 1.5 ml) which did
not affect cell viability for MCF7 breast cancer cells in vitro. Furthermore, a preliminary
Maximum Tolerated Dose (MTD) study was carried out and it shows no morbidity or
weight loss was observed for doses up to 400 mg/kg. The in vivo accumulation of the
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nanocapsules in the liver was evident under X-ray irradiation with 0.1 s exposure time.
Compared to the Gd2O2S:Eu without PSS/PAH mutilayers (Figure 4.17), the
accumulation rate for polyelectrolytes coated nanocapsules is slower in the first 1 h. Post
mortem, XEOL images of the excised organs confirmed that the nanocapsules
accumulated in liver and spleen (Figure 4.18).
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Figure 4.17 Representative luminescent images of accumulation of Gd2O2S:Eu
nanocapsules with and without polymer coating in mouse. (A) 5 min, (B) 1 h, (C) 6 h,
(D) 24 h after the mouse was injected with saline (200 µl). (E) 5 min, (F) 1 h, (G) 6 h,
(H) 24 h after the mouse was injected with Gd2O2S:Eu@PAH/PSS nanocapsules (200
µl, 1 mg/ml). (I) 5 min, (J) 1 h, (K) 6 h, (L) 24 h after the mouse was injected with
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Gd2O2S:Eu nanocapsules (200 µl, 1 mg/ml).

(M) Total radioluminescent intensity

counts as a function of time after injection. Reprinted with permission from ref. 126.
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Copyright 2012 American Chemical Society.
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Figure 4.18 Representative radioluminescent images of accumulation of Gd2O2S:Eu
nanocapsules with and without polymer coating in organs after 24 h. (A) Brain, (B)
Kidney, (C) Heart, (D) Fat, (E) Liver, (F) Lung, (G) Spleen, and (H) Muscle in the saline
injected mouse. (I) Brain, (J) Kidney, (K) Heart, (L) Fat, (M) Liver, (N) Lung, (O)
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Spleen, and (P) Muscle in the Gd2O2S:Eu@PAH/PSS nanocapsules (200 µl, 1 mg/ml)
injected mouse. (Q) Brain, (R) Kidney, (S) Heart, (T) Fat, (U) Liver, (V) Lung, (W)
Spleen, and (X) Muscle in the Gd2O2S:Eu nanocapsules (200 µl, 1 mg/ml) injected
mouse. Reprinted with permission from ref. 126. Copyright 2012 American Chemical
Society.
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Figure 4.19 The magnetic hysteresis loops of (A) Gd2O2S:Tb and (B) Gd2O2S:Eu.
Reprinted with permission from ref. 126. Copyright 2012 American Chemical Society.
Recent studies describe the synthesis and applications of gadolinium oxide
(Gd2O3) nanoparticles as MRI contrast agents.125, 139-143 However, to our knowledge, no
investigation of gadolinium oxysulfide based MRI contrast agents are reported so far.
Our luminescent nanocapsules mainly consisting of gadolinium oxysulfide (Gd2O2S) also
have similar magnetic properties with gadolinium oxide which make them a potential
MRI contrast agent and magnetic separation tool. The room temperature magnetic
hysteresis loops of nanocapsules (Gd2O2S:Tb, Gd2O2S:Eu) are shown in Figure 4.19. As
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the strength of the applied magnetic field increased, the linear correlation between the
magnetization and the applied magnetic field indicates the both Gd2O2S:Tb and
Gd2O2S:Eu nanocapsules are paramagnetic, with minimal hysteresis and a magnetic
susceptibility of 1.2×10-4 emu g-1 Oe-1 and showed no sign of saturation up to applied
fields of 30 kOe.
We performed in vitro MR assays (T2 and T2* weighted imaging) in 0.5% agarose
gel for both types of Gd2O2S:Tb and Gd2O2S:Eu nanocapsules with a series of
concentration (0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml). Figure 4.20 shows T2
and T2* weighted images after 3 ms. the proton relaxivities r2 of the nanocapsules was
determined from the longitudinal and transverse relaxation rates at various
concentrations. These relaxation rates are shown as a function of concentration in Figure
4.21. The relaxivities, r2 and r2* are 50.3 mM-1s-1 and 116.0 mM-1s-1 respectively for
Gd2O2S:Tb nanocapsules; 51.7 mM-1 s-1 and 116.4 mM-1s-1 for Gd2O2S:Eu nanocapsules.
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Figure 4.20 T2 and T2*-weighted images of radioluminescent nanocapsules. Group A:
T2-weighted images of Gd2O2S:Eu nanocapsules with concentration of 0.8 mg/ml, 0.4
mg/ml, 0.1 mg/ml, and 0.05 mg/ml. Group B: T2-weighted images of Gd2O2S:Tb with
concentration of 0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml. Group A*: T2*weighted images of Gd2O2S:Eu nanocapsules with concentration of 0.8 mg/ml, 0.4
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mg/ml, 0.1 mg/ml, and 0.05 mg/ml. Group B*: T2*-weighted images of Gd2O2S:Tb
nanocapsules with concentration of 0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml.
Reprinted with permission from ref. 126. Copyright 2012 American Chemical Society.
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Figure 4.21 MRI T2 and T2* relaxation rate curves as a function of Gd2O2S:Tb (A, C) and
Gd2O2S:Eu (B, D) concentration. Reprinted with permission from ref. 126. Copyright
2012 American Chemical Society.
For these nanocapsules, r2* is larger than r2 due to the inhomogeneities of local
static field from the magnetic moment of the particles. Previous work towards the
gadolinium nanoparticles (e. g. ultrasmall Gd2O3 nanoparticles (1~10 nm)139-142 and
hollow nanosparticles with thin Gd2O3 shell (~10 nm)143) reported that they can served as
good T1 contrast agents and moderate T2 contrast agents. However, our nanocapsules
with a ~25 nm Gd2O2S based nanoshell worked as a better T2 contrast agents compared
with Gd2O3 nanoparticles (r2=14.1~16.9 mM-1s-1)144-146 and gadolinium chelates (GdDTPA, 4.9 mM-1s-1)144 compared with some In addition, the T2 relaxivities value of our
nanocapsules has similar value with some FDA-approved iron oxide nanoparticle contrast
agents such as Ferumoxtran (Resovist®, 65 mM-1s-1), cross-linked iron oxide particle
(CLIO-Tat, 62 mM-1s-1), and water soluble iron oxide (WSIO, 78 mM-1s-1).147-150
Conclusion
In summary, we present a flexible template-directed method to produce
radioluminescent nanocapsules for a hydrophilic drug carrier and monitor release kinetics.
The release rate time constant was ~ 36 days at pH 7.4, and 21.4 hr at pH 5.0,
respectively. Importantly, the release mechanisms could be monitored in situ by tracking
the ratio of readioluminescence spectral peaks. Radioluminescence offers several
advantages over traditional optical imaging agents, including greater tissue penetration,
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elimination of autofluorescence, and the ability to perform high-resolution imaging
through thick tissue via functional X-ray Luminescence Tomography (FXLT)54-55, 112, 123.
Finally, the multifunctional nanocapsules combined the advantages of positive contrast of
radioluminescence and negative contrast of T2 weighted MR imaging. These capabilities
provide these nanocapsules to enable novel drug delivery and imaging modalities. In
future, we plan to target DOX loaded capsules to tumors and measure in situ release rates
and tumor growth for various nanocapsule sizes, shapes, and surface chemistries.
Experimental Section
Materials
Tetraethoxysilane (TEOS), poly(styrenesulfonate sodium) (PSS, MW:~70,000),
Iron (III) chloride anhydrous was purchased from Sigma-Aldrich (St. Louis, MO).
Gadolinium nitrate, europium nitrate, and poly(allylamine hydrochloride) (PAH,
MW:~15,000) were purchased from obtained from Alfa Aesar (Ward Hill, MA). Ethanol
(96%), urea, oxalic acid, ammonium hydroxide, and nitric acid were obtained from BDH
Chemicals Ltd (Poole, Dorset, UK). Deionized (DI) water was purchased from EMD
Chemicals Inc. (Gibbstown, NJ, USA). Polyvinylpyrrolidone (PVP K-30, MW 40,000)
was purchased from Spectrum Chemicals (Gardena, CA). Agarose (melting point 88±1
ºC) was purchased from Shelton Scientific (Peosta, IA). All chemicals were used as
received without further purification.
In vitro HPLC drug-release study and real-time drug release tacking: 100 µl of DOX
encapsulated nanocapsules with polyelectrolyte mutilayers (10 mg/ml) were suspended
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with release media (7 ml) at pH 5.0 and 7.4 in Slide-A-Lyzer MINI dialysis units at room
temperature. The release medium was removed for analysis at given time intervals, and
replaced with the same volume of fresh release medium. The DOX concentration was
measured with high performance liquid chromatography (HPLC) on a Waters system
using an Alltima C18 column (250×4.6 mm, 5 µm).
Radioluminescence drug release tracking experiment: 2 ml DOX encapsulated
nanocapsules with polyelectrolyte multilayers (25 mg/ml) were magnetically stirred at a
rate of 400 rpm in release media of either pH 5 or pH 7.4. 50 µl of the solution was taken
out for X-ray luminescence analysis without any separation at given time intervals.
Preparation of nanocapsules for MR Imaging: T2 and T2* MR measurements were
acquired for the spindle-shaped SiO2@Gd2O2S:Eu and Gd2O2S:Tb particles at a series of
concentrations (0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml). The particles were
dispersed in 0.5% agarose gel at 80 °C and cooled to room temperature in NRM tubes to
set the gel. The gel prevented settling and aggregation allowing MRI imaging several
days after preparation.
Cell viability test: MCF-7 breast cancer cells were seeded at a density of 10,000
cells/well in a 96-well plate. Cells were stored at 37 °C at 5% CO2 and attached to the
plate overnight. Nanocapsules were suspended in media, sonicated for 10 minutes to
disperse, and diluted to 250, 100, 50, and 10 µg/ml. Media was removed from wells and
fresh media or nanoparticle in media was added to each well. Five repeats were done for
each concentration. Nanoparticles were incubated with cells overnight and the next day a
Presto Blue assay (Life Technologies) was performed. Media was removed and 100 µl of
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a 1:9 ratio Presto Blue in culture media was added to each well. Cells were incubated at
37 °C and 5% CO2 for 45 minutes. Fluorescent intensity was taken with a plate reader
with an excitation wavelength of 560 nm and an emission wavelength of 590 nm.
Fluorescent intensity for each concentration of nanoparticle was normalized as a
percentage of the fluorescent intensity of the control cells. Percent viability averages
were plotted with error bars of one standard deviation.
Characterization methods: Transmission and scanning electron microscopy (TEM)
were performed on a H9500 operated at 200 kV and HD2000 microscope operated at 20
kV, respectively. Powder XRD patterns were obtained on a Rigaku diffractometer at 40
kV and 40 mA (CuKα radiation). For fluorescence spectra, 480 nm light was used to
excite the phosphors. To measure radioluminescence, X-ray was generated by a mini Xray tube (Amptek Inc. MA, USA), the X-ray tube was operated with tube voltage of 40
kV and tube current of 40 mA. The sample was mounted on a Leica Microscope (Leica
DMI 5000M, Wetzlar, Germany) equipped with a DeltaNu DNS 300 spectrometer
(Intevac-DeltaNu, Laramie, WY USA) with a 150 lines/mm grating blazed at 500 nm and
with a cooled CCD camera (iDUS-420BV, Andor, South Windsor, CT). X-ray
luminescence images were captured with an IVIS Lumina-XR Imaging System (Caliper
Life Sciences, Hopkinton, MA, US). Bright field and fluorescent images were taken on a
Nikon microscope (Eclipse Ti, Nikon, Melville, NY USA). Determination of the Zetapotential of the nanoparticles was performed via a Zetasizer Nano ZS (with a 633 nm HeNe laser) from Malvern Instrument. Prior to the experiment, the particles were diluted in
distilled water (0.1 mg/ml). Magnetization measurements were performed at the
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designated temperature using vibrating sample magnetometer (VSM) option of physical
property measurement system (PPMS, Quantum Design, USA), with the applied
magnetic field sweeping between +/- 3.0 Tesla at a rate of 50 Oe/sec. Determination of
the gadolinium content in a sample was performed by inductively coupled plasma (ICP)(Optima 3100 RL; Perkin-Elmer). All MRI experiments were performed on a Varian
4.7T horizontal bore imaging system (Agilent Inc, Santa Clara, CA). Samples, contained
in 5 mm NMR tubes, were placed in a 63 mm inner diameter quadrature RF coil for
imaging.
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CHAPTTER FIVE

V.
MAGNETIC AND OPTICAL PROPERTIES OF MULTIFUNCTIONAL
CORE-SHELL RADIOLUMINESCENCE NANOPARTICLES
Introduction
Multifunctional magnetic and fluorescent nanomaterials have attracted broad interest
because of their utility in biomedical applications such as bioimaging,151 drug delivery
carriers,152 magnetic resonance imaging (MRI),153 bio-separation,154 fluorescent
labeling,155-156 magnetic hyperthermia,157 and immunoassays.158 These magnetic particles
can be magnetically guided, oriented, heated, and imaged using external magnetic fields.
Meanwhile the particle fluorescence provides a sensitive label for imaging in cells and
thin tissue sections.
Although biological tissues are essentially transparent to magnetic fields which
facilitates in vivo magnetic control and imaging, fluorescence measurements are limited
in thick tissue due to autofluorescence backgrounds and optical scattering. X-ray
luminescence tomography (XLT) addresses these issues by using radioluminescent
contrast agents for low background, high resolution imaging in tissue.42,

159

Radioluminescence is well-suited for tissue imaging because both the X-ray excitation
and near-infrared (NIR) emission penetrate deeply through tissue and because unlabeled
tissues display minimal radioluminscence backgrounds. XLT images are generated by
scanning a narrow X-ray beam relative to the sample and detecting the diffuse light
escaping from the tissue using sensitive photodetectors. By restricting the X-ray
excitation to a single narrow beam, the origin of the optical photons can be inferred
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regardless of how many times these photons scatter in tissue and where they emerge from
the tissue. This enables tomography with a resolution limited by the X-ray beam width in
the tissue. The principle is similar to scanning confocal and structured illumination
optical microscopies, except that while multiphoton confocal microscopy is limited to
tissue thicknesses of 1 mm or less,82 XLT can image through several centimeters of tissue
because the X-rays are far less scattered than visible and NIR light. With a 1 mm X-ray
beam and 1–100 cGy radiation dose, Pratx et al. achieved a spatial resolution of 1 mm
through tissue-mimicking material based on the selective excitation of subpicomolar of
50 nm phosphor and optical detection of their luminescence.42 They also showed that
XLT could image the cross sectional distribution of microsize phosphor particles in 4.5
cm of an agar tissue phantom.41
Previously, we extended the XLT technique towards functional chemical imaging
on implanted phosphor films using X-ray excited optical luminescence as a local light
source for absorption spectroscopy of indicator dyes on the film surface. We developed a
radioluminescent pH-sensing film based upon indicator dye absorption, and demonstrated
0.3 mm knife-edge resolution imaging through 1 cm of chicken.112 We also imaged
patterns of silver deposition and dissolution on a phosphor film through 1 cm of pork
tissue.123 Our technique is uniquely suited for studying chemical changes on the surface
of implanted medical devices. The principle can also be extended to the third dimension
for using particles with indicator dyes.
Herein, we developed a novel and facile strategy to fabricate magnetic phosphors
for MRI and XLT imaging. Magnetic fluorescent and upconversion nanoparticles have
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previously been reported with an iron oxide core and rare earth doped NaYF4:Yb,Er
shell.160-161 However, a challenge is that iron oxide quenches most of the fluorescence if it
contacts the phosphor or is in proximity, even with a thin silica spacer layer.162-165 This
demonstrates that absorption in the core modulates the luminescence signal, which would
be a useful feature for generating chemical sensors with encapsulated indicators.
However, the iron oxide core decreases the luminescence intensity and leaves no space
for encapsulating drugs or dyes. In order to increase the luminescence intensity, we
partially etched the iron oxide core in oxalic acid. The particles’ optical and magnetic
properties depend upon the core size, which in is controlled by varying the etching time.
The etching process also produced a hollow space around the core which could be used
for drug and dye encapsulation.
Results and discussion
Our objective was to synthesize radioluminescent particles with controllable size,
shape, optical, and magnetic properties. We selected europium-doped gadolinium oxide
as a matrix because of its photostablity,166 its narrow and distinct spectral features under
fluorescence and radioluminescence,167-168 its MRI contrast,139-140,

142-143, 169

and its

relatively non-toxicicity.140, 142-143 We selected a core-shell template synthesis route so
that we could separately control the magnetic core and luminescent shell materials. Our
initial studies employed spindle-shaped hematite cores and therefore generated spindleshaped shells. However, the shape of the shell can be altered by using different core
shapes by changing the hematite synthesis conditions.132-133,

170

Although macrophage

uptake of particles with diameters larger than 500 nm reduces circulation time and is an
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obstacle to particulate drug delivery,171 there are some reports that changes in particle
shape strongly affect macrophage uptake and biodistribution. For example, Huang and
Decuzzi et al. studied the clearance of a series of non-spherical silica/silicon
nanoparticles with a length range of 300 nm~5 µm and observed that the particle shape
plays a crucial role in the circulation lifetime and biodistribution which are important for
drug delivery applications.127-128,

130

Champion and co-workers recently found that

macrophages internalize ellipsoid particles 2~6 µm long in a strongly orientationdependent manner. They observed that it took only a few minutes to internalize particles
with the high radius of curvature region contacting the macrophages, while particles
contacting the macrophages on their low curvature sides were not internalized within 12
h.129 Our long term goal will be to study how shape and size affect the biodistribution
using in situ XLT imaging.

Structure

and

morphology

of

magnetic

luminescent

nanoeyes

(γ-

Fe2O3@SiO2@Gd2O3:Eu)
The template core-shell synthesis process is presented in Figure 5.1. We first
synthesized a monodispersed spindle-shaped hematite core according to methods
described by Ozaki and co-workers.[21] Our particles were spindle shaped with an average
length of 400 nm and diameter of 80 nm, however, by varying the synthesis conditions,
the nanoparticle size can be tuned from 120 to 550 nm, and the aspect ratio from spheres
to prolate spheroids.132, 170 Hematite is a chemically stable antiferromagnetic phase of
iron oxide which can be later reduced to magnetite or iron and oxidized to ferrimagnetic
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maghemite (γ-Fe2O3). Hematite is used as a template because it is difficult to directly
synthesize uniform spindle magnetite or maghemite particles, and these large particles
often aggregate in magnetic fields especially at high particle concentration. The colloidal
hematite particles had a positive zeta potential of +26 mV which kept them well
dispersed in solution due to electrostatic repulsion. This positively charged hematite
could not be directly used as template for growing a phosphor shell because the positively
charged

hematite

would

repulse

the

positively

charged

phosphor

precursor

(Gd2O(CO3)2:Eu, +11 mV), see Figure 5.2. Instead, the hematite nanoparticles were first
treated through a modified Stöber procedure172 to deposit a thin silica layer which
reversed the surface charge (-36 mV), see Figure 5.3. A phosphor shell was then
successfully grown on these silica-modified hematite particles.
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Fe2O3@SiO2@Gd2O3:Eu), SEM (B) and TEM (C) image of nanoeyes. The inserted
figure in Figure 5.1A is the size distribution of nanoeyes. Reproduced from Ref. 125 with
permission from the Royal Society of Chemistry.
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500 nm
Figure 5.2 SEM images of growth of Gd2O(CO3)2:Eu on spindle-shaped hematite
nanoparticles without using an intermediate silica shell. Reproduced from Ref. 125 with
permission from the Royal Society of Chemistry.
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A

B

C

Figure 5.3 Zeta potential of (A) hematite nanorice (+26.1 mV), (B) Gd2O(CO3)2:Eu
(+11.1 mV), (C) silica coated hematite (-35.9 mV). Reproduced from Ref. 125 with
permission from the Royal Society of Chemistry.
To increase the luminescence of the core-shell structure, and provide a hollow space
for drug encapsulation, we etched the optically absorbing iron oxide core in oxalic acid
solution at 60 °C for a controlled period of time. The obtained α-Fe2O3@SiO2 particles
had a monodispersed spindle-shaped shell with a hollow space around the core and
appeared like “nanoeyes” in TEM images. After 9.5 h of etching, the magnetic cores of
these nanoeyes were cylinder-shaped with an average length of 150 nm and diameter of
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60 nm. In addition, the length of the iron oxide core was tunable from 0 to 400 nm with
different etching time (Figure 5.4, 5.6).

A

B

C

200 nm

200 nm

200 nm

Figure 5.4 TEM images of nanoeyes incubated in 0.5 M oxalic acid at 60 ºC for (A) 8.5
h, (B) 9.5 h, (C) 10 h. Reproduced from Ref. 125 with permission from the Royal Society
of Chemistry.
To synthesize radioluminescent particles, the silica-coated core-shell particles
were then coated with a layer of Gd2O(CO3)2:Eu through a homogeneous precipitation
method from gadolinium, europium nitrate. In order to convert the α-Fe2O3 to γ-Fe2O3,
the product above was treated by H2/N2 (5%/95%) at 450 °C for 3h and calcined later in
the air at 350 °C for 24 h. The resulting monodispersed nanoeyes (γFe2O3@SiO2@Gd2O3:Eu) had an average length of about 500 nm and diameter of 80 nm
(Figure 5.1B). They consisted of a ~10 nm silica intermediate shell and 40 nm phosphor
outer shell which could be distinguished in TEM images such as Figure 5.1C because of
the different electron penetrability between the Gd2O3, SiO2, and γ-Fe2O3 core.
X-ray diffraction (XRD) was performed on the nanocomposite samples in order to
investigate their structure and composition. Figure 5.5a shows the XRD pattern of the
precursor of nanoeyes (α-Fe2O3@SiO2@Gd2O(CO3)2:Eu). The X-ray diffraction pattern
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of α-Fe2O3 is clearly distinguished from the broad peak at about 30º from the porous
Gd2O(CO3)2:Eu. The XRD pattern of nanoeyes (Figure 5.5b) exhibits the characteristic
diffraction peaks of cubic structure of Gd2O3. The γ-Fe2O3 core peaks in Figure 5.5b are
indiscernibly weak because the cores have a small volume percentage and cross-section
compared to the Gd2O3. However, the XRD pattern of γ-Fe2O3 can be readily
distinguished under a thin shell (~10 nm) of Gd2O3:Eu (Figure 5.5c).
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Figure 5.5 XRD patterns of (a) precursor of nanoeye (α-Fe2O3@SiO2@Gd2O(CO3)2:Eu),
(b) nanoeye γ-Fe2O3@SiO2@Gd2O3:Eu (iron oxide core was incubated in oxalic acid for
9.5 h), (c) nanoeye (iron oxide core was incubated in oxalic acid for 9.5 h) with thin
Gd2O3:Eu shell (~10 nm). (▼: α- Fe2O3, ●: Gd2O3:Eu, ◆:γ-Fe2O3) Reproduced from
Ref. 125 with permission from the Royal Society of Chemistry.
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Magnetic and optical and properties of magnetic luminescent nanoparticles
In order to elucidate the magnetic properties of the nanoeyes, we synthesized
similar shell structures with solid iron oxide cores and hollow particles with dissolved
cores by incubation of the α-Fe2O3@SiO2 in oxalic acid for 0 h and 17 h, respectively
(Figure 5.6). The solid-core nanorice (γ- Fe2O3@SiO2@Gd2O3:Eu) and hollow nanorice
(SiO2@Gd2O3:Eu) both are monodispersed with a radioluminescent shell shape almost
identical to the nanoeyes (Figure 5.7).

A

B

200 nm

200 nm

Figure 5.6. TEM image of nanorice (A) and hollow nanorice (B). Reproduced from Ref.
125 with permission from the Royal Society of Chemistry.
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Figure 5.7 SEM images of nanorice (γ-Fe2O3@SiO2@Gd2O3:Eu, solid structure) (A) and
corresponding size distribution (B). SEM images of hollow nanorice (SiO2@Gd2O3:Eu)
(C), and corresponding size distribution (D). Reproduced from Ref. 125 with permission
from the Royal Society of Chemistry.
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Figure 5.8 The magnetic hysteresis loops of magnetic probes. (A) nanorice with
maghemite as the core, (B) nanoeyes (iron oxide core was incubated in oxalic acid for 9.5
h), (C) nanorice with hematite as the core, and (D) hollow nanorice. Bottom inset shows
the hysteresis loops of nanorice with hematite as the core and hollow nanorice. Top inset
show rapid (3 min) magnetophoretic separation of a solution of nanoeyes in a 1 cm
pathlength cuvette. Reproduced from Ref. 125 with permission from the Royal Society of
Chemistry.
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The room temperature magnetic hysteresis loops of magnetic nanorice, nanoeyes,
and hollow nanorice are shown in Figure 5.8. The hollow nanorice (SiO2@Gd2O3:Eu) are
paramagnetic, with minimal hysteresis and a magnetic susceptibility of 1.23×10-4 emu g-1
Oe-1 and showed no sign of saturation up to applied fields of 30 kOe. From the TEM
images (Figure 5.6) the core is approximately 13% of the volume and a similar
percentage of the mass. The iron oxide was converted to maghemite (γ-Fe2O3) via H2
reduction followed by oxidization in air (350 °C 24 h), and the particle colour changed
from red with the hematite core to brownish with the maghemite core. The nanorice
magnetization curve (Figure 5.8A) had two components, a hystertic ferrimagnetic (or
ferromagnetic) component with a coercivity of 308 Oe and a saturation magnetization of
~7.6 emu/g, and a paramagnetic component (linear slope at large applied fields). The
saturation magnetization of the ferrimagnetic component is approximately 10% of the
saturation magnetization of bulk γ-Fe2O3 (74 emu/g).173 These results are consistent with
a core ~10% maghemite by weight and a shell ~90% by weight which is also consistent
with the TEM images and ICP elemental analysis data. The hysteresis curve for nanoeye
(Figure 5.8B) had a smaller ferrimagnetic component with a saturation magnetization of
2.3 emu/g, which is consistent with a 3-fold reduction in weight per cent of maghemite.
The coercivity decreased to 165 Oe likely due to the decreases in the aspect ratio of the
iron oxide core. Although the saturation magnetization of the partially dissolved
nanoeyes is smaller than the nanorice, the magnetization is still strong enough for rapid
magnetophoretic separation (inset figure of Figure 5.8).
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In addition to magnetophoretic separation in magnetic field gradients, the
particles are expected to align with external magnetic fields due to their magnetic shape
anisotropy. This alignment is useful in developing sensitive and rapid immunoassays,
viscosity sensor, and improved intracellular sensors with orientation and shape-dependent
properties.174-176 For example, orientation of non-spherical particles has been shown to
affect phagocytosis rates for adherent macrophages.129,

177

In addition, the ability for

particles to rotate is useful for determining if particles are bound, while the rotation rate
in solution is useful for measuring viscosity and viscous drag.175 We demonstrate that the
magnetic nanoeyes rotate in response to a rotating external magnetic field by measuring
the scattering signal intensity as the particles rotate in response to a changing magnetic
field. Experimentally, we placed a solution of nanoeyes in

water/glycerol

(vwater:vglycerol=1:9) on a glass slide and observed the scattering intensity with a dark field
microscope. The nanoeyes were orientated by an external magnetic field which rotated by
90 º in every 3 s. As depicted in Figure 5.9, the scattering intensity was largest when the
particles were oriented parallel to the sample plane and presented the largest scattering
area. The scattering intensity decreased when the particles were oriented parallel to the
optical axis. Figure 5.9C shows the magnetically modulated optical scattering by the
nanoeyes. This rotational modulation cannot be observed for spherical particles which
have isotropic scattering properties.
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Figure 5.9 Schematic presentation of magnetic modulation of scattering of light (A, B) by
nanoeyes (iron oxide core was incubated in oxalic acid for 9.5 h), (C) Intensity time
series for nanoeyes under darkfield microscope. Reproduced from Ref. 125 with
permission from the Royal Society of Chemistry.

In addition to magnetic rotation and separation, the nanoeyes display fluorescence
under 480 nm excitation light and radioluminescence under X-ray excitation (Figure
5.10). The main emission peak of the Gd2O3:Eu phosphor shell with cubic structure was
observed at 610 nm, which corresponds to a red emission from the 5D0→7F2 Eu3+
transition. The fluorescence and radioluminescence of the solid core nanorice were hardly
detected. The luminescence quenching is likely due to inner filter effects as the 10 nm

109

silica shell spacer and hollow regions in the core would inhibit resonant energy transfer.
Previous approaches to address this quenching problem by separating the luminescent
shell from the absorptive core using a coating thick silica shell (>50 nm) also increase the
particle size.161, 165 By contrast, the current method of partial dissolving the iron oxide
core reduces the quenching while maintains the total nanoparticle size and volume. We
expect that carefully controlling dissolution time will allow optimization of the optical
and magnetic properties. In addition, a hollow space is formed around the iron oxide
core in the nanoeyes which could serve to encapsulate drugs for drug delivery
applications (See Figure 5.11). We expect that low molecular weight drugs can be loaded
into the hollow space of the particles.
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Figure 5.10 (A) Radioluminescence spectra of nanoeyes (iron oxide core was incubated
in oxalic acid for 9.5 h) and nanorice excited by X-ray, (B) Fluorescence spectra of
nanoeyes (iron oxide core was incubated in oxalic acid for 9.5 h) and nanorice excited by
480 nm light. Reproduced from Ref. 125 with permission from the Royal Society of
Chemistry.

110

A
Without dye

B
With dye

Without dye

C
With dye

Without dye

With dye

Figure 5.11 Photography of nanorice (A), nanoeyes (B), and hollow nanorice (C) without
and with bromocresol green dye encapsulated by a ~10 nm silica coating. Samples were
obtained after centrifuged for 15 min at 4000 rpm. Reproduced from Ref. 125 with
permission from the Royal Society of Chemistry.

Although the hollow nanorice obtained by completely dissolving the iron oxide are
paramagnetic, brightly luminescent, and have a large internal space for encapsulation,
their magnetic moment is weak compared to the solid nanorice and nanoeyes, especially
at low fields. As a result, they separate only very slowly with typical permanent magnetgenerated magnetic fields and field gradients. The nanorice particles with a solid iron
oxide core respond rapidly to magnetic fields but display only weak fluorescence and
negligible radioluminescence. In addition, there is not much space within the core for dye
and drug encapsulation. By partially dissolving the iron oxide core, nanoeyes are formed
which display magnetophoresis and radioluminescence. Their bright luminescence under
UV (365 nm) and X-ray irradiation is shown in Figure 2.12. Compared with the UV
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fluorescence, the X-ray luminescence of the nanoeyes provides a background-free image
which can be used for deep tissue imaging. The hollow regions in the nanoeyes could
also be used for indicator dye and drug encapsulation for theranostic applications. To test
whether the pores in the Gd2O3 shell were large enough for small molecules to diffuse
through, we incubated the nanoparticles in a solution of bromocresol blue dye,
encapsulated the dye and particle with ~ 10 nm silica layer, and washed and separated the
particles via centrifugation. The dye could indeed be encapsulated (see Figure 5.11),
while a control, the solid core particles could not encapsulate dye. We are currently
developing coatings to control the dye release rate.

A

B

Figure 5.12 Photograph of hollow nanorice under (A) UV light (365 nm) and (B) X-ray
luminescence. Reproduced from Ref. 125 with permission from the Royal Society of
Chemistry.
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Magnetic luminescent nanoparticles as T2 contrast agent
It is useful to have contrast agents that provide both radioluminescence and MRI
contrast in order to validate measurements, and provide complimentary information (e.g.
molecular information with functional XLT spectroscopy using indicators and tissue
contrast with MRI). Our magnetic radioluminescent particles are expected to serve as T2
and T2* contrast agents because of their strong magnetic moment in static MRI fields.
This is consistent with recent work showing that gadolinium oxide nanoparticles have
higher relaxivities compared with gadolinium chelates.169, 178-179
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Figure 5.13 T2 and T2*-weighted images of nanorice, nanoeyes (iron oxide core was
incubated in oxalic acid for 9.5 h), and hollow nanorice at echo time of 4 ms and 1.5 ms,
respectively. Group A: T2-weighted images of nanorice with concentration of 0.8 mg/ml,
0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml. Group B: T2-weighted images of nanoeyes with
concentration of 0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml. Group C: T2weighted images of hollow nanorice with concentration of 0.8 mg/ml, 0.4 mg/ml, 0.1
mg/ml, and 0.05 mg/ml. Group A*: T2-weighted images of nanorice with concentration
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of 0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml. Group B*: T2*-weighted images of
nanoeyes with concentration of 0.8 mg/ml, 0.4 mg/ml, 0.1 mg/ml, and 0.05 mg/ml. Group
C*: T2-weighted images of hollow nanorice with concentration of 0.8 mg/ml, 0.4 mg/ml,
0.1 mg/ml, and 0.05 mg/ml. Reproduced from Ref. 125 with permission from the Royal
Society of Chemistry.
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curves are approximately linear, although there is some evidence of saturation at the
highest concentration, 0.8 mg/ml. Fitting the points up to 0.4 mg/mL (2.6-3 mM), the
relaxivities, r2 and r2* are 68.73 mM-1s-1 and 274.11 mM-1s-1 respectively for the nanorice;
58.10 mM-1 s-1 and 120.43 mM-1s-1 for the nanoeyes, and 46.00 mM-1s-1 and 111.76 mM1 -1

s

for the hollow nanorice. The relaxivity is calculated based on the total molar

concentration of both Gd3+ and Fe3+. For comparison with other literature we have also
calculated r2 and r2* using the molar concentrations of just Gd3+ and Fe3+, and the total
mass concentration in mg/mL (see Table 5.2). For all particles, r2* is larger than r2
because r2 includes contributions from local static field inhomogeneities caused by the
magnetic moment of the particles. The difference between r2 and r2* may provide more
specificity towards the contrast agents, especially for the nanorice which display a factor
of 4 increased relaxivity. The iron oxide core significantly increased the relaxivities, with
the solid core providing the highest relaxivity and the hollow core the least.
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Table 5.1 ICP analysis of Gd3+ and Fe3+ in nanorice, nanoeyes, and hollow nanorice in
0.8, 0.4, 0.1, 0.05 mg/ml of solution.The 0 value for Fe3+ means < 0.01 mg/L, i.e. below
the limit of detection. Reproduced from Ref. 125 with permission from the Royal Society
of Chemistry.
Weight concentration
Type of nanoparticle
Nanorice
Gd3+
Fe3+
Nanoeyes
Gd3+
Fe3+
Hollow
Gd3+
nanorice
Fe3+

0.8 mg/ml

0.4 mg/ml

0.1 mg/ml

0.05 mg/ml

4.700 mM
1.200 mM
4.780 mM
0.730 mM
5.250 mM
0 mM

2.350 mM
0.600 mM
2.390 mM
0.365 mM
2.626 mM
0 mM

0.588 mM
0.150 mM
0.598 mM
0.091 mM
0.656 mM
0 mM

0.294 mM
0.075 mM
0.299 mM
0.046 mM
0.328 mM
0 mM

Table 5.2 r2 and r2* calculated based on molar concentration Gd3+, Fe3+, Gd3++Fe3+, and
weight concentration of particles. Reproduced from Ref. 125 with permission from the
Royal Society of Chemistry.
Relaxivity
r2
r2*
Type of nanoparticle
Weight concentration
514 ml mg-1s-1
2029 ml mg-1s-1
Molar concentration (Gd3+)
86.28 mM-1s-1
344.10 mM-1s-1
Nanorice
Molar concentration (Fe3+)
337.92 mM-1s-1 1347.71 mM-1s-1
3+
3+
Molar concentration (Gd +Fe )
68.73 mM-1s-1
274.11 mM-1s-1
Weight concentration
454 ml mg-1s-1
847 ml mg-1s-1
3+
-1 -1
Molar concentration (Gd )
66.97 mM s
138.82 mM-1s-1
Nanoeyes
Molar concentration (Fe3+)
438.54 mM-1s-1
909.00 mM-1s-1
Molar concentration (Gd3++Fe3+)
58.10 mM-1s-1
120.43 mM-1s-1
-1 -1
Hollow
Weight concentration
322 ml mg s
701 ml mg-1s-1
nanorice
Molar concentration (Gd3+)
46.00 mM-1s-1
111.76 mM-1s-1
Previous work showed that ultrasmall Gd2O3 nanoparticles (1~10 nm)139-142 and
hollow nanosparticles with thin Gd2O3 shell (~10 nm)143 served as good T1 contrast
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agents and moderate T2 contrast agents. In contrast, our spindle-shaped nanoparticles
with a ~40 nm Gd2O3:Eu shell worked better as a T2 contrast agents. This may be due to
low water exchange efficiency inside of the porous Gd2O3 nanoparticles, which is
consistent with earlier work by using the porous Gd2O3 nanoparticles (~200 nm in
diameter).143 Compared to FDA-approved iron oxide nanoparticle contrast agents such as
Ferumoxtran (Resovist®, 65 mM-1s-1),

cross-linked iron oxide particle (CLIO-Tat, 62

mM-1s-1), and water soluble iron oxide (WSIO, 78 mM-1s-1), our nanorice, nanoeyes, and
hollow nanorice had similar T2 relaxivities.147-150 However, these T2 relaxivities were
several times higher than typical gadolinium chelates (Gd-DTPA, 4.9 mM-1s-1)144 and
Gd2O3 nanoparticles (14.1~16.9 mM-1s-1).144-146 Most importantly, the contrast is
sufficient for many drug delivery applications. For example, 5~10 mg/mL is a typical
magnetic particle concentration in tumors for magnetic hyperthermia,180 while our
particles have several times faster relaxation rates than the gel even at the lowest
concentrations of 50 µg/mL (R2 is 37.7 s-1 for the nanorice, 29.3 s-1 for nanoeyes, and
20.0 s-1 for the hollow nanorice).

Nanoparticle Cytotoxicity Assay
Previous studies toxicity of ~80 nm iron oxide nanoparticles found no acute or
subacute toxic effects by histologic or serologic studies in rats or beagle dogs which
received a total of 3 mmol Fe/kg.181 In order to study the potential cytotoxicity of the rare
earth elements in the magnetic imaging probes (nanorice, nanoeyes, and hollow nanorice),
an in vitro cytotoxicity test of hollow nanorice was performed on MCF-7 breast cancer
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cells (Figure 5.16). The viability of the untreated cells was set as 100% in order to
calculate the viability of the cells treated by different concentration of X-ray phosphors.
Cell viability is not significantly affected by the Gd2O3:Eu nanoparticles up to
concentration of at least 250 µg/ml (24 hr exposure).
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Figure 5.16 Cytotoxicity test for hollow nanorice (Gd2O3:Eu). Reproduced from Ref. 125 with
permission from the Royal Society of Chemistry.

Conclusion
We successfully prepared magnetic luminescent nanoparticles using silica coated
hematite as a template. The silica coating plays a critical role on the growth of phosphor
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shell on the surface of the nanocores. After synthesis, the cores were made magnetic via
high temperature reduction in H2 and oxidization in air. The magnetic core size could be
controlled while preserving the luminescent shell by dissolving the core in oxalic acid.
Intermediate core sizes displayed both magnetic and luminescent properties. These novel
magnetic luminescent nanoparticles are advantageous because they allow for magnetic
separation and multimodal imaging with MRI, fluorescence and radioluminescence. We
expect that such nanocomposites, combining the advantages of magnetism and
luminescence, will find extensive applications in drug delivery and bioimaging. For
example, the hollow structure in the partially dissolved iron oxide phosphor can be
loaded with small dyes and drug molecules. Our synthesis technique is attractive because
multifunctional particles can be made by coating the core templates with multiple layers
of materials, each with a controlled thickness and composition. Different sizes, shapes
(spherical and non-spherical), and structures (hollow and non-hollow) can be obtained by
varying the shape and size of the hematite templates. Future work will study the effect of
size and shape on magnetic, luminescent, and bio-distribution properties.
Experimental Section
Materials
Iron (III) chloride anhydrous and tetraethoxysilane (TEOS) were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Gadolinium Nitrate, Europium nitrate,
potassium dihydrogen phosphate, and sulfur powder (99.5%) were purchased from
obtained from Alfa Aesar (Ward Hill, MA). Ethanol (anhydrous, denatured), urea,
oxalic acid, ammonium hydroxide, and nitric acid were obtained from BDH

120

Chemicals Ltd (Poole, Dorset, UK). Deionized (DI) water was purchased from EMD
Chemicals Inc. (Gibbstown, NJ, USA). Polyvinylpyrrolidone (PVP K-30, MW
40,000) was purchased from Spectrum Chemicals (Gardena, CA). Agarose (melting
point 88±1 ºC) was purchased from Shelton Scientific (Peosta, IA). All chemicals
were used as received without further purification.
Synthesis of spindle-shaped hematite particle
Monodispersed spindle-shaped hematite nanoparticles with controllable aspect
ratios were fabricated were prepared according to the method described by Ozaki and
coworkers182. Typically, 100 ml of aqueous solution containing 2.0×10-2 M FeCl3 and
4.0×10-4 M KH2PO4 were aged at 100 °C for 72 hours. The resulting precipitate was
centrifuged and washed three times with water.
Synthesis of spindle-shaped hematite particle with silica shell
To obtain momodispersed hematite-silica core-shell nanoparticles, the PVP
assisted coating method was used.183 The spindle-shaped hematite particles synthesized
above were dispersed ultrasonically to a 80 ml solution containing PVP (0.6 g), water (6
ml), and ethanol (74 ml). The suspension was stirred using a magnetic stir bar at room
temperature and a solution of TEOS (270 µl) in 20 ml ethanol was added, followed by 4
ml of ammonia hydroxide. After 3h, the reaction mixture was precipitated by centrifuging
at 4000 rpm for 16 min. The particles were washed three times with ethanol and
centrifuged to collect the product.
Synthesis of spindle-shaped magnetic phosphors
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The products above were suspended in 180 ml distilled water with 1.8 g PVP
and 11.34 g oxalic acid (0.5 M) incubated at 60 °C for certain time. The hematite
partially dissolved particles were collected by centrifugation and rinsed with DI water
twice. The obtained particles were resuspended with 3 ml Gd(NO3)3, 1.5 ml Eu(NO3)3
(80 mM), and 1.8 g PVP in pure water to form 300 ml of solution. 18 g of urea was added
to the solution and the solution was maintained at 80 °C for 90 min. The precursor of
magnetic phosphor was collected by centrifugation. The precursor of spindle-shaped
precursor was calcined in a furnace at 600 °C for 60 min. The powder was then
transferred to a tube furnace with a H2/N2 (5%/95%) flow at 450 °C for 3h. After that, the
sample was calcined in the tube furnace at 350 °C for 24 h.
Preparing nanocomposites for MR Imaging.
T2 and T2* MR measurements were acquired for the spindle-shaped γFe2O3@SiO2@Gd2O3:Eu particles at a series of concentrations (0.8 mg/ml, 0.4 mg/ml,
0.1 mg/ml, and 0.05 mg/ml). The particles were dispersed in 0.5% agarose gel at 80 °C
and cooled to room temperature in NRM tubes to set the gel. The gel prevented settling
and aggregation allowing MRI imaging several days after preparation.
Cell viability test
MCF-7 breast cancer cells were seeded at a density of 10,000 cells/well in a 96well plate. Cells were stored at 37 °C at 5% CO2 and attached to the plate overnight.
Nanoparticles were suspended in media, sonicated for 10 minutes to disperse, and diluted
to 250, 100, 50, and 10 µg/ml. Media was removed from wells and fresh media or
nanoparticle in media was added to each well. Five repeats were done for each
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concentration. Nanoparticles were incubated with cells overnight and the next day a
Presto Blue assay (Life Technologies) was performed. Media was removed and 100 µl of
a 1:9 ratio Presto Blue in culture media was added to each well. Cells were incubated at
37 °C and 5% CO2 for 45 minutes. Fluorescent intensity was taken with a plate reader
with an excitation wavelength of 560 nm and an emission wavelength of 590 nm.
Fluorescent intensity for each concentration of nanoparticle was normalized as a
percentage of the fluorescent intensity of the control cells. Percent viability averages
were plotted with error bars of one standard deviation.
Intrumentation
Transmission and scanning electron microscopy (TEM) were performed on a
H9500 operated at 300 kV and HD2000 microscope operated at 100 kV, respectively. An
X-ray diffractometer (Rigaku; MiniFlex, Cu Kα) was used to characterize the XRD
pattern of the magnetic phosphors. For fluorescence spectra, 480 nm light was used to
excite the phosphors.
To measure radioluminescence, X-ray was generated by a mini X-ray tube
(Amptek Inc. MA, USA), the X-ray tube was operated with tube voltage of 40 kV and
tube current of 99 µA. The sample was mounted on a Leica Microscope (Leica DMI
5000M, Wetzlar, Germany) equipped with a DeltaNu DNS 300 spectrometer (IntevacDeltaNu, Laramie, WY USA) with a 150 lines/mm grating blazed at 500 nm.
The Zeta-potential of the nanoparticles was determined using a Malvern
Instruments Zetasizer Nano ZS with a 633 nm He-Ne laser. Prior to the experiment, the
particles were diluted in distilled water (0.1 mg/ml). Magnetization measurements were
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performed at the designated temperature using vibrating sample magnetometer (VSM)
option of physical property measurement system (PPMS, Quantum Design, USA), with
the applied magnetic field sweeping between +/- 3.0 Tesla at a rate of 50 Oe/sec.
Determination of the gadolinium and iron content in a sample was performed by
inductively coupled plasma (ICP)- (Optima 3100 RL; Perkin-Elmer).
In order to magnetically modulate the optical scattering from the magnetic
luminescent particles, the particles were oriented and rotated in a magnetic field. A
permanent magnet (NdBFe, 1” in diameter, 3” in length, magnetized through its
diameter) was attached to a stepper motor and controlled by motion control software (Si
Programmer; Applied Motion Products, Watsonville, CV). Every 3s, the permanent
magnet was rotated 90º, first clockwise and then anticlockwise.
All MRI experiments were performed on a Varian 4.7T horizontal bore
imaging system (Agilent Inc, Santa Clara, CA). Samples, contained in 5 mm NMR
tubes, were placed in a 63 mm inner diameter quadrature RF coil for imaging. MRI
gradient echo scout images were collected in all three imaging planes (axial, coronal, and
sagittal) for subsequent image planning, with repetition time (TR) = 100 ms, echo time
(TE) = 4 ms, number of slices =20, slice thickness =2, matrix size 128×128, field of view
(FOV) = 40 mm×40 mm, number of acquisitions (NEX) =2. Relaxivity measurements
were then collected on a single 2 mm thick imaging slice, approximately perpendicular to
the long axis of the NMR tubes. The single slice, with FOV = 36 mm×36 mm, was
imaged using a T2-weighted multi-spin echo imaging sequence with TR = 3000, NEX =
10, echo spacing = 4ms, number of echoes = 10, and 128 x 128 matrix. T2*-weighted
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images were collected using a gradient echo imaging sequence with TR = 500 ms, flip =
20°, 128×128 matrix, NEX = 10, and echo times = [1.5, 3, 4.5, 9, 15 ms]. Following data
collection, images were analyzed using Matlab 2011a (The Mathworks, Inc., Natick,
MA). Regions of interest (ROI’s), encompassing approximately 70-80 voxels, were
manually drawn in each sample, and the signals from those voxels averaged to obtain a
mean signal for each sample. The same ROI was used to calculate the mean signal of the
sample across all echo times.
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CHAPTER SIX

VI. CONCLUSIONS AND FUTURE DERECTIONS
In chapter II and III, we developed a novel technique (XEOL) for in situ
chemical imaging through tissue with high spatial resolution. When the X-ray excited
luminescence combines with suitable chemical sensing dyes (fluorescent and colorimetric
indicators), a background-free radioluminescence based pH sensor was fabricated. The
high spatial resolution (0.30 mm) through 10 mm of chicken breast was demonstrated by
detecting a two-color X-ray phosphor film. We then extended the XEOL technique to
imaging silver dissolution under 10 mm pork where it also offers a combination of high
spatial resolution (limited by the X-ray beam width) and high sensitivity optical detection.
Fluorescent and colorimetric indicators and stains are widely used for histology and
biomedical research because of their high sensitivity and specificity for a wide variety of
analytes. XEOL indicators combine the advantages of optical indicators with high
resolution, low background imaging from scanning X-ray excitation. A particularly
attractive application is imaging chemical (e.g biofilm) and mechanical changes on
implanted medical devices, which can become infected. Many analytes can be measured
(e.g. pH, silver metal dissolution, oxygen, and protease activity). Relatively thick
phosphor films may be used to improve X-ray luminescence capture, and signal strength
especially at high energies. The two dimensional nature of the surfaces simplifies and
speeds up imaging. An important challenge will be to minimize the spectral distortion
caused by wavelength dependent tissue scattering and absorption, especially for deeply
implanted devices. Several techniques are possible, including calculation of spectral
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ratios using closely spaced spectral peaks, use of spectral reference regions near to the
sensor region, and lifetime-based imaging. Another technical challenge will be
integrating the sensor film onto the implanted device while minimizing delamination,
abrasion, and reducing bacterial adhesion. After sensor development, the next step will be
integration of sensing with active components such as combining magnetic or
photothermal hyperthermia and drug release with local pH sensors to monitor the effect
of therapies on local biofilm chemistry.
In addition to chemical analysis on surfaces, XEOL can be used for three
dimensional tomography similar to X-ray luminescence tomography (XLT) and limitedangle XLT. For example, our group has developed hollow nanoparticles with
encapsulated magnetic iron oxide nanoparticles. The luminescence is quenched by iron
oxide in the core and increases as the iron oxide is etched.125 We have also encapsulated
indicator dyes and are studying leaching rate as a function of pH. In future we expect that
these types of sensors will be useful for local drug delivery while measuring the amount
of drug delivered in time. Additional sensors with unique optical emission spectra can be
used for simultaneously studying changes in cellular chemistry such as endosomal pH
changes upon apoptosis. Such in situ sensors will be useful for optimizing therapeutic
agents and monitoring effectiveness.
Future work involves using chemical indicator dyes for oxygen and other
analytes, using narrower X-ray beams and more sensitive detection optics for two
dimensional chemical imaging and tomography, and developing a portable imaging
system. Two dimensional chemical imaging will be especially useful for measuring
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chemical changes on a surface, such as in situ detection of acidosis, hypoxia, and
hydroxyapatite degradation on implanted devices with bacterial colonies. Phosphoresent
lifetime measurements are alternative approaches which do not depend on scattering or
absorption. We may also measure the lifetime of long-lived Oxygen sensing molecules
such as Ru(dpp) or platinum complexes. These dyes are quenched by oxygen and serve
as oxygen sensors. We can also use phosphors with relatively fast decay time to
distinguish the lifetime of the chemical indicator from the phosphors or use long lifetime
phosphors and measure the quenching lifetime caused by adsorbed acceptor molecules or
plasmonic nanoparticles. Recent developments in X-ray imaging and contrast agents are
opening up new opportunities for high-resolution functional imaging. In all cases, a key
advantage of XEOL is that high resolution images can be generated because X-rays can
penetrate deeply through tissue and have relatively low scattering coefficients. The
images can also be co-registered with structural information from X-ray attenuation
imaging and integrated with other imaging techniques such as diffuse optical
fluorescence tomography and MRI. The main disadvantage of X-ray imaging, however,
is that large X-ray doses cause short term tissue damage/radiation sickness, and increase
the long term risk of developing cancer.47, 184-185 Consequently, the challenge will be to
maximize the analytical sensitivity, specificity, image resolution, and acquisition rate
while minimizing the X-ray dose, contrast concentration, and contrast toxicity. The use of
up-conversion nanophosphors which are able to emit visible light under near infrared
light excitation is alterative approach to address the safety concern of X-ray but at cost of
spatial resolution.186-187
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A wide variety of contrast agents with unique spectra have been developed for
phosphor film applications and these can be used for X-ray luminescence tomography
contrast (see Table. 1). New X-ray excited luminescent nanoparticles are expected to
explored to meet the application of XEOL. High optical collection efficiencies are also
required using large area photodetectors and potentially integrating sphere optics. In
limited angle configurations the X-ray luminescence tomography images can be acquired
rapidly, although with some loss of resolution along one dimension.56 We expect that
continuing

development

of

phosphor

nanomaterials,

targeting

moieties,

and

instrumentation will greatly expand the utility of X-ray luminescence tomography. Many
of the phosphor materials also have large magnetic permeability and serve as effective
MRI contrast agents.125
In Chapter IV, we present a flexible template-directed method to produce nonsphrical radioluminescent nanocapsules for an anticancer drug (DOX) carrier, monitor
release kinetics, and magnetic drug carrier. The hollow radioluminescence nanocapsules
demonstrate a multifunctional platform with an X-ray excited optical luminescence
(XEOL) spectrum that changes during drug release. These nanocapsules are also
paramagnetic, allowing them to be used as MRI imaging agents. The future work will
focus on the study of toxicity of DOX loaded nanocapsules, pH dependent drug release in
vivo, target DOX loaded capsules to tumors, and measure in situ release rates and tumor
growth for various nanocapsule sizes, shapes, and surface chemistries. In order to reduce
required X-ray dose to capsule enough X-ray excited luminescence, more studies will
focus on enhance the luminescence of anophosphors. Some templates such as carbon
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nanospheres which can be decomposed in the synthesis of nanophosphors is one of the
approaches to simplify the process of nanocarrier synthesis. Some flux (Na2CO3, NaF,
etc.) used in traditional solid reaction can successfully improve the luminescence of Xray phosphors. However, the size (> 1 μm) of phosphors are not suitable for molecular
imaging or drug delivery. Novel method based on the use of flux are promising to obtain
ultrabright X-ray phosphor in nanosize. Combination of up conversion phosphors which
can be excited by near infrared and emit visible light with X-ray phosphor is alternative
approach to reduce the dose of X-ray used to locate the drug nanocarrier.
Chapter V provides a partially etching method to fabricated magnetic
luminescent nanocapsules. These magnetic capsules can serve good contrast agent for
XEOL, T2 weighted MRI, and magnetic nanocarriers. In the future, we plan to target the
tumor in vivo by applying magnetic field on the drug loaded magnetic capsules. Novel
method should also be explored to improve the luminescence intensity such as the use of
flux to improve the X-ray excited luminescence or coating brighter up-conversion
phosphor on iron oxide nancores. In order to increase the saturated magnetization of the
nanocarriers, fabricating stronger magnetic materials such as pure iron nanoparticles need
be studied because these materials shows ultra-high saturated magnetization (212
emu/g)188 and relaxivity (330 mM-1s-1) for T2-weighted magnetic resonance imaging 189.
Overall, XEOL-based multifunctional X-ray nanophosphors are highly
promising for rapid and sensitive chemical analysis in tissue or the surface of implanted
medical devices. With further improvements in instrumentation and contrast agents, we
expect a bright future for high resolution molecular imaging with X-ray nanophosphors.
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